https://trial.medpath.com/news/global-hiv-aids-crisis-latest-statistics-show-40-million-living-with-hiv-as-prevention-and-treatment-options-expand 2025-01-03T10:31:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-hiv-aids-crisis-latest-statistics-show-40-million-living-with-hiv-as-prevention-and-treatment-options-expand 2025-01-03T10:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/cathworks-completes-enrolment-in-cad-treatment-system-trial 2025-01-03T09:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cathworks-completes-enrolment-in-cad-treatment-system-trial 2025-01-03T09:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/deeper-response-predicts-better-outcomes-in-high-risk-smoldering-myeloma-nature 2025-01-03T09:21:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deeper-response-predicts-better-outcomes-in-high-risk-smoldering-myeloma-nature 2025-01-03T09:21:31+00:00 hourly 0.9 https://trial.medpath.com/news/belite-bio-awaits-phase-iii-dragon-trial-data-can-it-fuel-further-gains 2025-01-03T09:20:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belite-bio-awaits-phase-iii-dragon-trial-data-can-it-fuel-further-gains 2025-01-03T09:20:01+00:00 hourly 0.9 https://trial.medpath.com/news/integrated-pharmacists-significantly-improve-ibd-treatment-outcomes-and-cost-savings 2025-01-03T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/integrated-pharmacists-significantly-improve-ibd-treatment-outcomes-and-cost-savings 2025-01-03T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-nucala-mepolizumab-approved-in-china-for-treatment-of-adults-with-chronic 2025-01-03T07:41:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-nucala-mepolizumab-approved-in-china-for-treatment-of-adults-with-chronic 2025-01-03T07:41:30+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-surgeon-general-pushes-for-enhanced-cancer-warning-labels-on-alcohol-products 2025-01-03T07:22:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-surgeon-general-pushes-for-enhanced-cancer-warning-labels-on-alcohol-products 2025-01-03T07:22:34+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-approves-wockhardt-s-drug-miqnaf-to-treat-cabp-in-adults-the-hindu 2025-01-03T06:30:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-approves-wockhardt-s-drug-miqnaf-to-treat-cabp-in-adults-the-hindu 2025-01-03T06:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/lexaria-bioscience-corp-to-file-ind-application-with-fda-for-phase-1b-hypertension-clinical-trial 2025-01-03T04:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexaria-bioscience-corp-to-file-ind-application-with-fda-for-phase-1b-hypertension-clinical-trial 2025-01-03T04:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-moves-to-join-lawsuit-over-glp-1-compounding-as-fda-deadline-approaches 2025-01-03T04:05:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-moves-to-join-lawsuit-over-glp-1-compounding-as-fda-deadline-approaches 2025-01-03T04:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/sichuan-baili-tianheng-pharmaceutical-co-ltd-voluntarily-disclosed-the-inclusion-of-bl 2025-01-03T03:52:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sichuan-baili-tianheng-pharmaceutical-co-ltd-voluntarily-disclosed-the-inclusion-of-bl 2025-01-03T03:52:45+00:00 hourly 0.9 https://trial.medpath.com/news/complement-factor-h-targeting-antibody-gt103-in-refractory-non-small-cell-lung-cancer 2025-01-03T02:23:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/complement-factor-h-targeting-antibody-gt103-in-refractory-non-small-cell-lung-cancer 2025-01-03T02:23:27+00:00 hourly 0.9 https://trial.medpath.com/news/trump-s-health-nominees-raise-concerns-over-wellness-industry-influence-on-public-health-policy 2025-01-03T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-s-health-nominees-raise-concerns-over-wellness-industry-influence-on-public-health-policy 2025-01-03T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/intravenous-liposomal-irinotecan-in-metastatic-triple-negative-breast-cancer-after-2-prior 2025-01-03T01:36:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intravenous-liposomal-irinotecan-in-metastatic-triple-negative-breast-cancer-after-2-prior 2025-01-03T01:36:32+00:00 hourly 0.9 https://trial.medpath.com/news/acelyrin-inc-to-host-virtual-investor-event-to-share-new-phase-2-data-and-morningstar 2025-01-03T01:28:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acelyrin-inc-to-host-virtual-investor-event-to-share-new-phase-2-data-and-morningstar 2025-01-03T01:28:06+00:00 hourly 0.9 https://trial.medpath.com/news/orchestra-biomed-shares-get-shot-in-the-arm-on-solid-clinical-trial-data 2025-01-03T00:22:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orchestra-biomed-shares-get-shot-in-the-arm-on-solid-clinical-trial-data 2025-01-03T00:22:51+00:00 hourly 0.9 https://trial.medpath.com/news/what-s-going-on-with-acelyrin-shares-friday 2025-01-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/what-s-going-on-with-acelyrin-shares-friday 2025-01-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-generation-of-car-t-therapy-shows-promise-in-treating-cll 2025-01-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-generation-of-car-t-therapy-shows-promise-in-treating-cll 2025-01-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nasal-swab-test-successfully-distinguishes-between-asthma-subtypes-in-breakthrough-study 2025-01-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-nasal-swab-test-successfully-distinguishes-between-asthma-subtypes-in-breakthrough-study 2025-01-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/imugene-doses-first-australian-patient-in-phase-1b-azer-cel-clinical-trial-proactive-investors 2025-01-02T23:41:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imugene-doses-first-australian-patient-in-phase-1b-azer-cel-clinical-trial-proactive-investors 2025-01-02T23:41:11+00:00 hourly 0.9 https://trial.medpath.com/news/bipolar-androgen-therapy-rationale-candidate-patients-and-latest-evidence-for-mcrpc-patients 2025-01-02T23:36:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bipolar-androgen-therapy-rationale-candidate-patients-and-latest-evidence-for-mcrpc-patients 2025-01-02T23:36:37+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ib-initial-data-loncastuximab-tesirine-lpyl-plus-glofitamab-effective-safe-in-dlbcl 2025-01-02T23:20:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-ib-initial-data-loncastuximab-tesirine-lpyl-plus-glofitamab-effective-safe-in-dlbcl 2025-01-02T23:20:48+00:00 hourly 0.9 https://trial.medpath.com/news/boosting-reliability-ema-backs-ai-tool-for-mash-trials-citeline-news-insights 2025-01-02T22:39:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boosting-reliability-ema-backs-ai-tool-for-mash-trials-citeline-news-insights 2025-01-02T22:39:02+00:00 hourly 0.9 https://trial.medpath.com/news/gi-alliance-offers-clinical-trial-opportunities-in-the-dallas-fort-worth-area-locations 2025-01-02T21:53:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gi-alliance-offers-clinical-trial-opportunities-in-the-dallas-fort-worth-area-locations 2025-01-02T21:53:46+00:00 hourly 0.9 https://trial.medpath.com/news/alx-oncology-faces-mixed-outcomes-in-clinical-trials-and-executive-changes 2025-01-02T21:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alx-oncology-faces-mixed-outcomes-in-clinical-trials-and-executive-changes 2025-01-02T21:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/pembrolizumab-plus-sbrt-fails-to-improve-survival-in-unresected-stage-i-ii-nsclc 2025-01-02T21:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pembrolizumab-plus-sbrt-fails-to-improve-survival-in-unresected-stage-i-ii-nsclc 2025-01-02T21:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/very-low-dose-rituximab-for-cad-may-not-sustainably-kill-b-cells 2025-01-02T20:05:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/very-low-dose-rituximab-for-cad-may-not-sustainably-kill-b-cells 2025-01-02T20:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/results-from-nicotinamide-trial-highlighted-uci-mind 2025-01-02T19:19:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/results-from-nicotinamide-trial-highlighted-uci-mind 2025-01-02T19:19:01+00:00 hourly 0.9 https://trial.medpath.com/news/top-10-liver-disease-stories-of-2024 2025-01-02T19:03:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/top-10-liver-disease-stories-of-2024 2025-01-02T19:03:22+00:00 hourly 0.9 https://trial.medpath.com/news/college-of-medicine-researcher-receives-grant-to-further-pediatric-oncology-research 2025-01-02T18:46:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/college-of-medicine-researcher-receives-grant-to-further-pediatric-oncology-research 2025-01-02T18:46:15+00:00 hourly 0.9 https://trial.medpath.com/news/azd0486-shows-good-efficacy-in-relapsed-refractory-follicular-lymphoma 2025-01-02T18:36:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/azd0486-shows-good-efficacy-in-relapsed-refractory-follicular-lymphoma 2025-01-02T18:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/hanx-biopharmaceuticals-ltd-announces-first-patient-dosing-in-first-in-human-phase-1 2025-01-02T18:12:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hanx-biopharmaceuticals-ltd-announces-first-patient-dosing-in-first-in-human-phase-1 2025-01-02T18:12:20+00:00 hourly 0.9 https://trial.medpath.com/news/top-10-fabry-disease-news-stories-of-2024 2025-01-02T17:46:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/top-10-fabry-disease-news-stories-of-2024 2025-01-02T17:46:11+00:00 hourly 0.9 https://trial.medpath.com/news/poolbeg-startles-investors-with-plan-to-hook-up-with-hookipa-citeline-news-insights 2025-01-02T16:54:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/poolbeg-startles-investors-with-plan-to-hook-up-with-hookipa-citeline-news-insights 2025-01-02T16:54:20+00:00 hourly 0.9 https://trial.medpath.com/news/capricor-completes-bla-submission-to-the-fda-for 2025-01-02T16:52:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capricor-completes-bla-submission-to-the-fda-for 2025-01-02T16:52:56+00:00 hourly 0.9 https://trial.medpath.com/news/for-alzheimer-agitation-a-novel-oral-nmda-inhibitor-could-be-the-next-targeted-treatment 2025-01-02T16:36:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/for-alzheimer-agitation-a-novel-oral-nmda-inhibitor-could-be-the-next-targeted-treatment 2025-01-02T16:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/jiangsu-recbio-technology-co-ltd-announces-completion-of-phase-iii-clinical-trial-of-the 2025-01-02T16:26:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jiangsu-recbio-technology-co-ltd-announces-completion-of-phase-iii-clinical-trial-of-the 2025-01-02T16:26:17+00:00 hourly 0.9 https://trial.medpath.com/news/os-therapies-to-attend-the-43rd-annual-jp-morgan-healthcare-conference-stock-titan 2025-01-02T16:20:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/os-therapies-to-attend-the-43rd-annual-jp-morgan-healthcare-conference-stock-titan 2025-01-02T16:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/study-of-sacituzumab-govitecan-misses-os-end-point-in-pretreated-urothelial-carcinoma 2025-01-02T15:06:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-of-sacituzumab-govitecan-misses-os-end-point-in-pretreated-urothelial-carcinoma 2025-01-02T15:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/how-retail-pharmacies-are-bringing-clinical-trials-to-the-community 2025-01-02T14:51:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/how-retail-pharmacies-are-bringing-clinical-trials-to-the-community 2025-01-02T14:51:47+00:00 hourly 0.9 https://trial.medpath.com/news/hemostemix-is-up-listing-in-the-usa-to-generate-liquidity-stock-titan 2025-01-02T14:41:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemostemix-is-up-listing-in-the-usa-to-generate-liquidity-stock-titan 2025-01-02T14:41:12+00:00 hourly 0.9 https://trial.medpath.com/news/base-treatment-decisions-in-metastatic-breast-cancer-on-presence-of-esr1-mutations 2025-01-02T14:39:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/base-treatment-decisions-in-metastatic-breast-cancer-on-presence-of-esr1-mutations 2025-01-02T14:39:43+00:00 hourly 0.9 https://trial.medpath.com/news/avalo-therapeutics-appoints-jennifer-riley-as-chief-strategy-officer-biospace 2025-01-02T14:37:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avalo-therapeutics-appoints-jennifer-riley-as-chief-strategy-officer-biospace 2025-01-02T14:37:30+00:00 hourly 0.9 https://trial.medpath.com/news/capricor-files-landmark-fda-application-for-first-ever-dmd-cardiomyopathy-treatment 2025-01-02T14:21:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capricor-files-landmark-fda-application-for-first-ever-dmd-cardiomyopathy-treatment 2025-01-02T14:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/benzodiazepine-agonist-treatment-for-patients-with-benzodiazepine-dependence-trials 2025-01-02T14:14:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/benzodiazepine-agonist-treatment-for-patients-with-benzodiazepine-dependence-trials 2025-01-02T14:14:23+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-car-t-cell-therapy-shrinks-tumors-in-children-with-deadly-brain-cancer 2025-01-02T14:00:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-car-t-cell-therapy-shrinks-tumors-in-children-with-deadly-brain-cancer 2025-01-02T14:00:49+00:00 hourly 0.9 https://trial.medpath.com/news/silo-pharma-advances-ptsd-drug-spc-15-toward-clinical-trials-plans-2025-ind-filing 2025-01-02T13:55:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silo-pharma-advances-ptsd-drug-spc-15-toward-clinical-trials-plans-2025-ind-filing 2025-01-02T13:55:36+00:00 hourly 0.9 https://trial.medpath.com/news/neumora-s-antidepressant-stumbles-in-first-phase-3-trial-readout-stat-news 2025-01-02T13:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neumora-s-antidepressant-stumbles-in-first-phase-3-trial-readout-stat-news 2025-01-02T13:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/cgtlive-s-2024-pillars-of-progress-top-news-in-lysosomal-disorders 2025-01-02T13:15:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cgtlive-s-2024-pillars-of-progress-top-news-in-lysosomal-disorders 2025-01-02T13:15:55+00:00 hourly 0.9 https://trial.medpath.com/news/new-south-wales-to-introduce-year-long-pill-testing-trial-at-music-festivals-mixmag 2025-01-02T13:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-south-wales-to-introduce-year-long-pill-testing-trial-at-music-festivals-mixmag 2025-01-02T13:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/phone-app-may-help-treat-opioid-use-disorder-data-suggests 2025-01-02T12:39:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phone-app-may-help-treat-opioid-use-disorder-data-suggests 2025-01-02T12:39:49+00:00 hourly 0.9 https://trial.medpath.com/news/nervgen-completes-enrollment-in-chronic-cohort-of-its-phase-1b-2a-clinical-trial-of-nvg 2025-01-02T12:38:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nervgen-completes-enrollment-in-chronic-cohort-of-its-phase-1b-2a-clinical-trial-of-nvg 2025-01-02T12:38:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-and-ema-feedback-endorses-vididencel-registration-trial-preparations-firstword-pharma 2025-01-02T12:31:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-and-ema-feedback-endorses-vididencel-registration-trial-preparations-firstword-pharma 2025-01-02T12:31:10+00:00 hourly 0.9 https://trial.medpath.com/news/iit-guwahati-develops-precision-drug-hydrogel-for-cancer-treatment-with-fewer-side-effects 2025-01-02T12:15:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iit-guwahati-develops-precision-drug-hydrogel-for-cancer-treatment-with-fewer-side-effects 2025-01-02T12:15:42+00:00 hourly 0.9 https://trial.medpath.com/news/sangamo-s-stock-plummets-as-pfizer-axes-hemophilia-gene-therapy-pact-biospace 2025-01-02T12:05:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sangamo-s-stock-plummets-as-pfizer-axes-hemophilia-gene-therapy-pact-biospace 2025-01-02T12:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/shattuck-labs-provides-corporate-update-and-highlights-upcoming-key-milestones-in-2025 2025-01-02T12:05:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shattuck-labs-provides-corporate-update-and-highlights-upcoming-key-milestones-in-2025 2025-01-02T12:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/high-rate-of-asymptomatic-pulmonary-involvement-found-in-early-ra-and-psa-patients 2025-01-02T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-rate-of-asymptomatic-pulmonary-involvement-found-in-early-ra-and-psa-patients 2025-01-02T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/priority-health-expands-midwest-presence-with-acquisition-of-physicians-health-plan-of-northern-indiana 2025-01-02T11:36:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/priority-health-expands-midwest-presence-with-acquisition-of-physicians-health-plan-of-northern-indiana 2025-01-02T11:36:27+00:00 hourly 0.9 https://trial.medpath.com/news/new-framework-proposed-to-improve-hidradenitis-suppurativa-diagnosis-and-treatment-alignment 2025-01-02T11:23:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-framework-proposed-to-improve-hidradenitis-suppurativa-diagnosis-and-treatment-alignment 2025-01-02T11:23:47+00:00 hourly 0.9 https://trial.medpath.com/news/empagliflozin-in-nondiabetic-individuals-with-calcium-and-uric-acid-kidney-stones-nature 2025-01-02T11:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/empagliflozin-in-nondiabetic-individuals-with-calcium-and-uric-acid-kidney-stones-nature 2025-01-02T11:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/neurologylive-r-year-in-review-2024-most-listened-podcast-episodes 2025-01-02T11:05:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurologylive-r-year-in-review-2024-most-listened-podcast-episodes 2025-01-02T11:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/gastroenterology-month-in-review-december-2024-hcplive 2025-01-02T11:03:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gastroenterology-month-in-review-december-2024-hcplive 2025-01-02T11:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-insights-of-keynote-522-regimen-adoption-for-treating-triple-negative-breast-cancer 2025-01-02T10:57:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-insights-of-keynote-522-regimen-adoption-for-treating-triple-negative-breast-cancer 2025-01-02T10:57:31+00:00 hourly 0.9 https://trial.medpath.com/news/psilocybin-shows-potential-for-treating-mental-health-disorders-in-people-with-cancer-and-addiction 2025-01-02T10:46:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psilocybin-shows-potential-for-treating-mental-health-disorders-in-people-with-cancer-and-addiction 2025-01-02T10:46:34+00:00 hourly 0.9 https://trial.medpath.com/news/mural-oncology-set-for-key-data-readouts-in-2025-for-nemvaleukin-alfa-in-ovarian 2025-01-02T10:34:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mural-oncology-set-for-key-data-readouts-in-2025-for-nemvaleukin-alfa-in-ovarian 2025-01-02T10:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/olanzapine-samidorphan-effects-on-weight-gain-an-individual-patient-data-meta-analysis 2025-01-02T10:16:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olanzapine-samidorphan-effects-on-weight-gain-an-individual-patient-data-meta-analysis 2025-01-02T10:16:13+00:00 hourly 0.9 https://trial.medpath.com/news/global-trial-finding-a-cure-for-rare-childhood-cancer-opens-university-of-birmingham 2025-01-02T09:50:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-trial-finding-a-cure-for-rare-childhood-cancer-opens-university-of-birmingham 2025-01-02T09:50:17+00:00 hourly 0.9 https://trial.medpath.com/news/gyre-therapeutics-on-track-for-key-data-readouts-and-product-launches-in-2025 2025-01-02T09:34:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gyre-therapeutics-on-track-for-key-data-readouts-and-product-launches-in-2025 2025-01-02T09:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-and-roche-collaborate-on-promising-lung-cancer-therapy 2025-01-02T09:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovent-and-roche-collaborate-on-promising-lung-cancer-therapy 2025-01-02T09:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/cspc-pharmaceutical-gains-breakthrough-status-for-cancer-therapy-tipranks-com 2025-01-02T09:18:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cspc-pharmaceutical-gains-breakthrough-status-for-cancer-therapy-tipranks-com 2025-01-02T09:18:31+00:00 hourly 0.9 https://trial.medpath.com/news/patient-enrollment-concluded-early-in-pegasus-phase-3-pemphigus-trial-for-rilzabrutinib 2025-01-02T08:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-enrollment-concluded-early-in-pegasus-phase-3-pemphigus-trial-for-rilzabrutinib 2025-01-02T08:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-higher-mortality-and-complication-rates-for-esophagectomy-at-private-equity-owned-hospitals 2025-01-02T08:41:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-higher-mortality-and-complication-rates-for-esophagectomy-at-private-equity-owned-hospitals 2025-01-02T08:41:03+00:00 hourly 0.9 https://trial.medpath.com/news/redefining-value-metrics-in-cancer-care-swedish-cancer-institute-director-calls-for-reform 2025-01-02T07:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redefining-value-metrics-in-cancer-care-swedish-cancer-institute-director-calls-for-reform 2025-01-02T07:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/colorado-launches-psilocybin-therapy-program-amid-regulatory-debates-and-veterans-advocacy 2025-01-02T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/colorado-launches-psilocybin-therapy-program-amid-regulatory-debates-and-veterans-advocacy 2025-01-02T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/travel-burden-analysis-reveals-higher-costs-for-epcoritamab-treatment-in-lymphoma-patients 2025-01-02T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/travel-burden-analysis-reveals-higher-costs-for-epcoritamab-treatment-in-lymphoma-patients 2025-01-02T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-faces-whistleblower-lawsuit-over-alleged-ms-drug-kickback-scheme 2025-01-02T05:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-faces-whistleblower-lawsuit-over-alleged-ms-drug-kickback-scheme 2025-01-02T05:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/pioneer-in-pediatric-leukemia-treatment-transforms-global-outcomes-through-four-decades-at-st-jude 2025-01-02T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pioneer-in-pediatric-leukemia-treatment-transforms-global-outcomes-through-four-decades-at-st-jude 2025-01-02T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/zhaoke-ophthalmology-reports-positive-trial-results-for-tab014-markets-insider 2025-01-02T03:37:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zhaoke-ophthalmology-reports-positive-trial-results-for-tab014-markets-insider 2025-01-02T03:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-abandons-hemophilia-a-gene-therapy-program-returns-rights-to-sangamo 2025-01-02T03:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-abandons-hemophilia-a-gene-therapy-program-returns-rights-to-sangamo 2025-01-02T03:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-stocks-facing-fda-decision-in-january-2025-rttnews 2025-01-02T02:55:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-stocks-facing-fda-decision-in-january-2025-rttnews 2025-01-02T02:55:36+00:00 hourly 0.9 https://trial.medpath.com/news/critical-treatment-gap-persists-for-t2-low-asthma-despite-therapeutic-advances 2025-01-02T02:54:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/critical-treatment-gap-persists-for-t2-low-asthma-despite-therapeutic-advances 2025-01-02T02:54:54+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-brings-clinical-trial-site-addition-and-change-of-pi-applications-to-online-mode 2025-01-02T02:49:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-brings-clinical-trial-site-addition-and-change-of-pi-applications-to-online-mode 2025-01-02T02:49:57+00:00 hourly 0.9 https://trial.medpath.com/news/hk-inno-n-speeds-up-developing-homegrown-obesity-drug-pharma-article-kbr 2025-01-02T02:43:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hk-inno-n-speeds-up-developing-homegrown-obesity-drug-pharma-article-kbr 2025-01-02T02:43:48+00:00 hourly 0.9 https://trial.medpath.com/news/china-emerges-as-global-leader-in-rare-disease-clinical-trials-since-2020 2025-01-02T02:39:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-emerges-as-global-leader-in-rare-disease-clinical-trials-since-2020 2025-01-02T02:39:20+00:00 hourly 0.9 https://trial.medpath.com/news/korea-approves-rare-pediatric-chondrodysplasia-drug-voxzogo-policy-article-kbr 2025-01-02T02:38:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korea-approves-rare-pediatric-chondrodysplasia-drug-voxzogo-policy-article-kbr 2025-01-02T02:38:41+00:00 hourly 0.9 https://trial.medpath.com/news/ai-revolutionizes-atopic-dermatitis-diagnosis-and-monitoring-with-advanced-technology-solutions 2025-01-02T02:31:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-revolutionizes-atopic-dermatitis-diagnosis-and-monitoring-with-advanced-technology-solutions 2025-01-02T02:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-england-achieves-record-breaking-58-7-early-cancer-detection-rate-despite-treatment-access-challenges 2025-01-02T01:53:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-england-achieves-record-breaking-58-7-early-cancer-detection-rate-despite-treatment-access-challenges 2025-01-02T01:53:09+00:00 hourly 0.9 https://trial.medpath.com/news/will-tarlatamab-an-sclc-drug-developed-with-korea-s-help-be-introduced-here-this-year 2025-01-02T01:49:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/will-tarlatamab-an-sclc-drug-developed-with-korea-s-help-be-introduced-here-this-year 2025-01-02T01:49:16+00:00 hourly 0.9 https://trial.medpath.com/news/patient-centric-strategies-reshape-oncology-trial-success-industry-experts-call-for-enhanced-engagement 2025-01-02T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-centric-strategies-reshape-oncology-trial-success-industry-experts-call-for-enhanced-engagement 2025-01-02T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tnf-inhibitors-reduce-fracture-risk-in-axial-spondyloarthritis-patients 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tnf-inhibitors-reduce-fracture-risk-in-axial-spondyloarthritis-patients 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-micurx-s-mrx-5-for-ntm-infections 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-micurx-s-mrx-5-for-ntm-infections 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/valo-health-halts-development-of-eye-disease-drug-seeks-partnership 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valo-health-halts-development-of-eye-disease-drug-seeks-partnership 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-systems-news-events 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-systems-news-events 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-rejects-neuraxpharm-and-apellis-drugs-companies-to-appeal 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-rejects-neuraxpharm-and-apellis-drugs-companies-to-appeal 2025-01-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/immunization-most-read-stories-from-2024-drug-topics 2025-01-01T21:12:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunization-most-read-stories-from-2024-drug-topics 2025-01-01T21:12:51+00:00 hourly 0.9 https://trial.medpath.com/news/jefferies-starts-rhythm-pharmaceuticals-with-buy-on-obesity-potential-markets-insider 2025-01-01T18:46:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jefferies-starts-rhythm-pharmaceuticals-with-buy-on-obesity-potential-markets-insider 2025-01-01T18:46:13+00:00 hourly 0.9 https://trial.medpath.com/news/merck-gets-u-k-approval-for-sotatercept-for-pah-msn 2025-01-01T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-gets-u-k-approval-for-sotatercept-for-pah-msn 2025-01-01T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/sleep-quality-similar-between-youth-with-sickle-cell-disease-and-healthy-controls-but-quality-of-life-differs 2025-01-01T16:10:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sleep-quality-similar-between-youth-with-sickle-cell-disease-and-healthy-controls-but-quality-of-life-differs 2025-01-01T16:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/tempest-announces-agreement-with-roche-to-support-advancement-of-amezalpat 2025-01-01T16:06:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempest-announces-agreement-with-roche-to-support-advancement-of-amezalpat 2025-01-01T16:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/pipeline-watch-thirteen-approvals-and-eight-phase-iii-readouts 2025-01-01T15:40:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pipeline-watch-thirteen-approvals-and-eight-phase-iii-readouts 2025-01-01T15:40:56+00:00 hourly 0.9 https://trial.medpath.com/news/zongertinib-continues-to-improve-outcomes-in-advanced-her2-mutant-nsclc 2025-01-01T15:06:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zongertinib-continues-to-improve-outcomes-in-advanced-her2-mutant-nsclc 2025-01-01T15:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/study-protocol-for-covid-19-breakthrough-infections-and-vaccine-induced-immune-plos 2025-01-01T12:03:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-protocol-for-covid-19-breakthrough-infections-and-vaccine-induced-immune-plos 2025-01-01T12:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/cinema-program-tackles-therapeutic-inertia-in-cardiometabolic-care-through-multi-faceted-approach 2025-01-01T11:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cinema-program-tackles-therapeutic-inertia-in-cardiometabolic-care-through-multi-faceted-approach 2025-01-01T11:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/expert-outlines-personalized-monitoring-approach-for-myeloproliferative-neoplasm-management 2025-01-01T10:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expert-outlines-personalized-monitoring-approach-for-myeloproliferative-neoplasm-management 2025-01-01T10:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/japan-approves-daiichi-sankyo-s-trop-2-adc-for-breast-cancer-bioworld 2025-01-01T10:15:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-approves-daiichi-sankyo-s-trop-2-adc-for-breast-cancer-bioworld 2025-01-01T10:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/news-in-brief-sotyktu-phase-iii-win-novo-s-alhemo-approval-axsome-agitation-data-pfizer 2025-01-01T09:40:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/news-in-brief-sotyktu-phase-iii-win-novo-s-alhemo-approval-axsome-agitation-data-pfizer 2025-01-01T09:40:50+00:00 hourly 0.9 https://trial.medpath.com/news/importance-of-including-paediatric-experts-in-clinical-trials 2025-01-01T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/importance-of-including-paediatric-experts-in-clinical-trials 2025-01-01T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/a-novel-non-opioid-multimodal-analgesic-from-xgene-pharmaceutical-reduces-pain-and-a 2025-01-01T07:43:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-novel-non-opioid-multimodal-analgesic-from-xgene-pharmaceutical-reduces-pain-and-a 2025-01-01T07:43:55+00:00 hourly 0.9 https://trial.medpath.com/news/iv-push-antibiotics-show-promise-for-faster-treatment-in-septic-shock-patients 2025-01-01T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iv-push-antibiotics-show-promise-for-faster-treatment-in-septic-shock-patients 2025-01-01T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/experts-debate-car-t-cell-therapy-options-comparing-yescarta-and-breyanzi-for-lymphoma-treatment 2025-01-01T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experts-debate-car-t-cell-therapy-options-comparing-yescarta-and-breyanzi-for-lymphoma-treatment 2025-01-01T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/scisparc-advances-autism-treatment-trial-cbd-based-sci-210-gets-key-israeli-approval 2025-01-01T06:54:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scisparc-advances-autism-treatment-trial-cbd-based-sci-210-gets-key-israeli-approval 2025-01-01T06:54:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-faces-legal-challenge-over-tirzepatide-shortage-list-removal-agrees-to-reevaluation 2025-01-01T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-faces-legal-challenge-over-tirzepatide-shortage-list-removal-agrees-to-reevaluation 2025-01-01T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/penn-medicine-s-lynn-schuchter-three-decades-of-pioneering-melanoma-treatment-and-research 2025-01-01T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/penn-medicine-s-lynn-schuchter-three-decades-of-pioneering-melanoma-treatment-and-research 2025-01-01T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/accc-fall-2024-innovations-in-clinical-trial-access-patient-care-and-treatment-authorization 2025-01-01T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accc-fall-2024-innovations-in-clinical-trial-access-patient-care-and-treatment-authorization 2025-01-01T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/liquid-biopsies-transform-lung-cancer-diagnostics-with-5-day-result-turnaround 2025-01-01T05:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liquid-biopsies-transform-lung-cancer-diagnostics-with-5-day-result-turnaround 2025-01-01T05:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/oncology-fellows-journal-seeks-input-to-shape-future-content-for-hematology-oncology-trainees 2025-01-01T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncology-fellows-journal-seeks-input-to-shape-future-content-for-hematology-oncology-trainees 2025-01-01T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-covid-19-causes-more-severe-kidney-function-decline-than-pneumonia 2025-01-01T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-covid-19-causes-more-severe-kidney-function-decline-than-pneumonia 2025-01-01T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cadrenal-therapeutics-provides-2024-year-end-company-update-reinforcing-clinical 2025-01-01T02:29:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cadrenal-therapeutics-provides-2024-year-end-company-update-reinforcing-clinical 2025-01-01T02:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/carsgen-announces-the-initiation-of-an-investigator-initiated-trial-for-an-allogeneic-cd19 2025-01-01T02:29:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carsgen-announces-the-initiation-of-an-investigator-initiated-trial-for-an-allogeneic-cd19 2025-01-01T02:29:19+00:00 hourly 0.9 https://trial.medpath.com/news/cystic-fibrosis-sophie-pierce-ready-to-row-the-atlantic-bbc 2025-01-01T02:24:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cystic-fibrosis-sophie-pierce-ready-to-row-the-atlantic-bbc 2025-01-01T02:24:28+00:00 hourly 0.9 https://trial.medpath.com/news/looking-ahead-to-2025-dermatology-drug-approvals 2025-01-01T02:13:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/looking-ahead-to-2025-dermatology-drug-approvals 2025-01-01T02:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/advancing-lung-cancer-treatment-with-bispecific-antibodies-a-review-of-amivantamab 2025-01-01T02:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancing-lung-cancer-treatment-with-bispecific-antibodies-a-review-of-amivantamab 2025-01-01T02:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/at-19-by-shanghai-yake-biotechnology-for-follicular-lymphoma-likelihood-of-approval 2025-01-01T00:26:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/at-19-by-shanghai-yake-biotechnology-for-follicular-lymphoma-likelihood-of-approval 2025-01-01T00:26:30+00:00 hourly 0.9 https://trial.medpath.com/news/top-5-most-read-articles-on-myasthenia-gravis-in-2024 2025-01-01T00:22:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/top-5-most-read-articles-on-myasthenia-gravis-in-2024 2025-01-01T00:22:41+00:00 hourly 0.9 https://trial.medpath.com/news/ema-issues-positive-opinion-on-poltreg-s-pediatric-investigation-plan-for-type-1-diabetes-treg-therapy 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-issues-positive-opinion-on-poltreg-s-pediatric-investigation-plan-for-type-1-diabetes-treg-therapy 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nivolumab-shows-promise-in-refractory-biliary-tract-cancer-with-22-response-rate-in-phase-ii-trial 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nivolumab-shows-promise-in-refractory-biliary-tract-cancer-with-22-response-rate-in-phase-ii-trial 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-sciences-announces-11-billion-investment-in-us-drug-manufacturing-expansion 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-sciences-announces-11-billion-investment-in-us-drug-manufacturing-expansion 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/systimmune-to-present-updated-izalontamab-brengitecan-data-for-her2-negative-breast-cancer-at-esmo-breast-2025 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/systimmune-to-present-updated-izalontamab-brengitecan-data-for-her2-negative-breast-cancer-at-esmo-breast-2025 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaceutical-asset-purchase-deals-show-sustained-growth-since-2019-report-reveals 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaceutical-asset-purchase-deals-show-sustained-growth-since-2019-report-reveals 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/itepekimab-met-the-primary-endpoint-in-one-of-two-copd-phase-3 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/itepekimab-met-the-primary-endpoint-in-one-of-two-copd-phase-3 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/visugromab-plus-nivolumab-shows-promise-in-anti-pd-1-refractory-solid-tumors-by-targeting-gdf-15-pathway 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/visugromab-plus-nivolumab-shows-promise-in-anti-pd-1-refractory-solid-tumors-by-targeting-gdf-15-pathway 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/doxorubicin-plus-pembrolizumab-shows-promise-in-phase-2-trial-for-advanced-soft-tissue-sarcoma 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/doxorubicin-plus-pembrolizumab-shows-promise-in-phase-2-trial-for-advanced-soft-tissue-sarcoma 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-proposes-update-to-18-year-guidance-on-developing-biologics-biosimilars-and-vaccines 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-proposes-update-to-18-year-guidance-on-developing-biologics-biosimilars-and-vaccines 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alpha-cognition-s-oral-therapy-zunveyl-r-receives-fda-approval-to-treat 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alpha-cognition-s-oral-therapy-zunveyl-r-receives-fda-approval-to-treat 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a-new-horizon-in-alzheimers-disease-targeting-highly-neurotoxic-amyloid-b-oligomers-abos 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-new-horizon-in-alzheimers-disease-targeting-highly-neurotoxic-amyloid-b-oligomers-abos 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a-phase-1-study-of-tyra-300-in-people-with-advanced 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-phase-1-study-of-tyra-300-in-people-with-advanced 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/beigene-s-brukinsa-approved-by-swissmedic-for-waldenstroms-macroglobulinemia-treatment 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beigene-s-brukinsa-approved-by-swissmedic-for-waldenstroms-macroglobulinemia-treatment 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/an-efficacy-and-safety-study-of-rpt193-in-adults-with-atopic 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/an-efficacy-and-safety-study-of-rpt193-in-adults-with-atopic 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-on-inhaled-fexlamose-for-treating-moderate-to-severe-copd-in-adults 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-on-inhaled-fexlamose-for-treating-moderate-to-severe-copd-in-adults 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/recce-pharmaceuticals-secures-strategic-patent-protection-in-china-for-antimicrobial-technology 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recce-pharmaceuticals-secures-strategic-patent-protection-in-china-for-antimicrobial-technology 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ionis-reports-positive-phase-3-results-for-olezarsen-in-familial-chylomicronemia-syndrome 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ionis-reports-positive-phase-3-results-for-olezarsen-in-familial-chylomicronemia-syndrome 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-gsk-s-nucala-for-copd-treatment-expanding-therapeutic-options 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-gsk-s-nucala-for-copd-treatment-expanding-therapeutic-options 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/scisparc-secures-japanese-patent-for-pain-relief-combo-by-x 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scisparc-secures-japanese-patent-for-pain-relief-combo-by-x 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-deputy-commissioner-signals-potential-reforms-to-pdufa-program 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-deputy-commissioner-signals-potential-reforms-to-pdufa-program 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/compass-pathways-psilocybin-drug-meets-primary-endpoint-in-phase-3-trial-despite-market-disappointment 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/compass-pathways-psilocybin-drug-meets-primary-endpoint-in-phase-3-trial-despite-market-disappointment 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/upc-rejects-boehringer-ingelheim-s-preliminary-injunction-against-zentiva-s-generic-nintedanib 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/upc-rejects-boehringer-ingelheim-s-preliminary-injunction-against-zentiva-s-generic-nintedanib 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dana-farber-cancer-institute-launches-phase-ii-trials-testing-immunotherapy-in-meningioma-and-melanoma 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dana-farber-cancer-institute-launches-phase-ii-trials-testing-immunotherapy-in-meningioma-and-melanoma 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cytomx-therapeutics-initiates-combination-therapy-arm-in-phase-1-melanoma-trial 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytomx-therapeutics-initiates-combination-therapy-arm-in-phase-1-melanoma-trial 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/arch-biopartners-announces-financing-and-clinical-trial-progress 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arch-biopartners-announces-financing-and-clinical-trial-progress 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/beigene-launches-global-phase-2-trial-of-zanubrutinib-for-relapsed-or-refractory-marginal-zone-lymphoma 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beigene-launches-global-phase-2-trial-of-zanubrutinib-for-relapsed-or-refractory-marginal-zone-lymphoma 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/schizophrenia-today-what-s-new-and-what-s-coming 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/schizophrenia-today-what-s-new-and-what-s-coming 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/circassia-receives-fda-boost-for-copd-drugs-in-the-us 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circassia-receives-fda-boost-for-copd-drugs-in-the-us 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-human-trial-finds-a-dopamine-continuous-intracerebroventricular 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-human-trial-finds-a-dopamine-continuous-intracerebroventricular 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a-real-world-study-to-gain-clinical-insights-into-faricimab-fareal-study 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-real-world-study-to-gain-clinical-insights-into-faricimab-fareal-study 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-and-iteos-halt-development-of-tigit-immunotherapy-after-failed-lung-cancer-trial 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-and-iteos-halt-development-of-tigit-immunotherapy-after-failed-lung-cancer-trial 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/intensified-total-neoadjuvant-therapy-in-patients-with 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intensified-total-neoadjuvant-therapy-in-patients-with 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bladder-tumor-focused-adaptive-radiotherapy-clinical-outcomes-and-feasibility 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bladder-tumor-focused-adaptive-radiotherapy-clinical-outcomes-and-feasibility 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/beigene-s-brukinsa-receives-european-commission-approval-for-cll-treatment 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beigene-s-brukinsa-receives-european-commission-approval-for-cll-treatment 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/advancements-in-antibiotic-development-for-gram-negative-bacteria 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancements-in-antibiotic-development-for-gram-negative-bacteria 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/beigene-announces-positive-phase-3-trial-results-for-tislelizumab-in-nasopharyngeal-cancer 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beigene-announces-positive-phase-3-trial-results-for-tislelizumab-in-nasopharyngeal-cancer 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/two-phase-iii-trials-target-advanced-breast-cancer-with-novel-therapeutic-approaches 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-phase-iii-trials-target-advanced-breast-cancer-with-novel-therapeutic-approaches 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-study-of-tti-101-for-advanced-liver-cancer-patients 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-study-of-tti-101-for-advanced-liver-cancer-patients 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-trial-tests-yoga-as-non-pharmacological-treatment-for-chemotherapy-induced-peripheral-neuropathy 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-trial-tests-yoga-as-non-pharmacological-treatment-for-chemotherapy-induced-peripheral-neuropathy 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-evaluates-new-treatment-for-non-healing-diabetic-foot-ulcers 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-evaluates-new-treatment-for-non-healing-diabetic-foot-ulcers 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-to-acquire-23andme-for-310-million-gaining-access-to-vast-genetic-database 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-to-acquire-23andme-for-310-million-gaining-access-to-vast-genetic-database 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/scienture-secures-fda-orange-book-patent-listing-for-arblitm-losartan-potassium-oral-suspension 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scienture-secures-fda-orange-book-patent-listing-for-arblitm-losartan-potassium-oral-suspension 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aerpio-initiates-phase-2-trial-of-razuprotafib-for-covid-19-blood-vessel-damage 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aerpio-initiates-phase-2-trial-of-razuprotafib-for-covid-19-blood-vessel-damage 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abeona-therapeutics-sells-priority-review-voucher-as-nppa-sets-prices-for-84-new-drugs 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abeona-therapeutics-sells-priority-review-voucher-as-nppa-sets-prices-for-84-new-drugs 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-upar-targeting-imaging-agent-fg001-shows-promise-in-oral-and-oropharyngeal-cancer-surgery 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-upar-targeting-imaging-agent-fg001-shows-promise-in-oral-and-oropharyngeal-cancer-surgery 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-moves-antibiotic-against-superbug-into-phase-3-of-testing-x 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-moves-antibiotic-against-superbug-into-phase-3-of-testing-x 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/global-clinical-trials-review-on-friedreich-ataxia-for-2024 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-clinical-trials-review-on-friedreich-ataxia-for-2024 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/beigene-initiates-phase-i-clinical-trial-of-bgb-a317-in-china 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beigene-initiates-phase-i-clinical-trial-of-bgb-a317-in-china 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-directs-covid-19-vaccine-manufacturers-to-update-formulations-for-fall-2024 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-directs-covid-19-vaccine-manufacturers-to-update-formulations-for-fall-2024 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-teal-health-s-at-home-hpv-test-expanding-cervical-cancer-screening-access 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-teal-health-s-at-home-hpv-test-expanding-cervical-cancer-screening-access 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-advances-v181-quadrivalent-dengue-vaccine-candidate-toward-june-2025-milestone 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-advances-v181-quadrivalent-dengue-vaccine-candidate-toward-june-2025-milestone 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/actuate-therapeutics-reports-significant-survival-improvement-in-metastatic-pancreatic-cancer-phase-2-trial 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actuate-therapeutics-reports-significant-survival-improvement-in-metastatic-pancreatic-cancer-phase-2-trial 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-human-study-for-resistant-epilepsy-using-vagus-nerve-stimulation-device 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-human-study-for-resistant-epilepsy-using-vagus-nerve-stimulation-device 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/acadia-pharmaceuticals-announces-business-and-pipeline-updates-at-j-p-morgan-healthcare-conference 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acadia-pharmaceuticals-announces-business-and-pipeline-updates-at-j-p-morgan-healthcare-conference 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-trial-compares-proton-therapy-to-standard-radiation-for-leptomeningeal-metastasis-from-breast-and-lung-cancers 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-trial-compares-proton-therapy-to-standard-radiation-for-leptomeningeal-metastasis-from-breast-and-lung-cancers 2025-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/flot-combination-takes-the-lead-in-localized-ge-cancer-targeted-oncology 2024-12-31T22:08:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/flot-combination-takes-the-lead-in-localized-ge-cancer-targeted-oncology 2024-12-31T22:08:21+00:00 weekly 0.7 https://trial.medpath.com/news/omega-therapeutics-stock-hits-52-week-low-amid-financial-and-market-challenges 2024-12-31T20:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/omega-therapeutics-stock-hits-52-week-low-amid-financial-and-market-challenges 2024-12-31T20:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/contagion-s-2024-top-stories-hepatitis-infections 2024-12-31T19:59:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/contagion-s-2024-top-stories-hepatitis-infections 2024-12-31T19:59:21+00:00 weekly 0.7 https://trial.medpath.com/news/merck-wins-uk-approval-for-lung-disease-drug-acquired-in-11-billion-deal-westlaw-today 2024-12-31T19:52:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-wins-uk-approval-for-lung-disease-drug-acquired-in-11-billion-deal-westlaw-today 2024-12-31T19:52:37+00:00 weekly 0.7 https://trial.medpath.com/news/veru-announces-the-sale-of-the-fc2-female-condom-r-internal-globenewswire 2024-12-31T19:32:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/veru-announces-the-sale-of-the-fc2-female-condom-r-internal-globenewswire 2024-12-31T19:32:06+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-s-2024-pillars-of-progress-top-news-in-hematology 2024-12-31T19:15:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cgtlive-s-2024-pillars-of-progress-top-news-in-hematology 2024-12-31T19:15:31+00:00 weekly 0.7 https://trial.medpath.com/news/kazia-therapeutics-provides-update-on-paxalisib-regulatory-pathway-following-type-c 2024-12-31T19:09:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kazia-therapeutics-provides-update-on-paxalisib-regulatory-pathway-following-type-c 2024-12-31T19:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/explore-the-evolving-role-of-btk-inhibitors-in-cll-with-alexey-danilov-md-phd-onclive 2024-12-31T19:07:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/explore-the-evolving-role-of-btk-inhibitors-in-cll-with-alexey-danilov-md-phd-onclive 2024-12-31T19:07:00+00:00 weekly 0.7 https://trial.medpath.com/news/immunocompromised-adults-show-weaker-response-to-rsv-vaccines-news-medical 2024-12-31T16:38:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunocompromised-adults-show-weaker-response-to-rsv-vaccines-news-medical 2024-12-31T16:38:11+00:00 weekly 0.7 https://trial.medpath.com/news/leqselvi-approval-tops-healio-s-most-read-alopecia-news-in-2024 2024-12-31T15:55:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leqselvi-approval-tops-healio-s-most-read-alopecia-news-in-2024 2024-12-31T15:55:10+00:00 weekly 0.7 https://trial.medpath.com/news/kazia-therapeutics-shares-fall-after-fda-declines-accelerated-drug-approval 2024-12-31T15:29:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kazia-therapeutics-shares-fall-after-fda-declines-accelerated-drug-approval 2024-12-31T15:29:30+00:00 weekly 0.7 https://trial.medpath.com/news/brii-bio-announces-signing-of-asset-purchase-agreements-acquiring-brii-179-ip-rights 2024-12-31T15:29:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brii-bio-announces-signing-of-asset-purchase-agreements-acquiring-brii-179-ip-rights 2024-12-31T15:29:13+00:00 weekly 0.7 https://trial.medpath.com/news/ec-approves-rybrevant-lazcluze-for-advanced-nsclc-treatment 2024-12-31T15:22:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ec-approves-rybrevant-lazcluze-for-advanced-nsclc-treatment 2024-12-31T15:22:56+00:00 weekly 0.7 https://trial.medpath.com/news/miracle-new-drug-trial-shrinks-cruel-aggressive-bladder-cancer-uk-news-daily-express 2024-12-31T15:11:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/miracle-new-drug-trial-shrinks-cruel-aggressive-bladder-cancer-uk-news-daily-express 2024-12-31T15:11:20+00:00 weekly 0.7 https://trial.medpath.com/news/corcept-therapeutics-submits-new-drug-application-for-relacorilant-to-treat-cushing-s-syndrome 2024-12-31T14:39:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corcept-therapeutics-submits-new-drug-application-for-relacorilant-to-treat-cushing-s-syndrome 2024-12-31T14:39:09+00:00 weekly 0.7 https://trial.medpath.com/news/diabetes-drug-appears-to-fight-lung-cancer-but-only-in-overweight-or-obese-patients 2024-12-31T14:06:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diabetes-drug-appears-to-fight-lung-cancer-but-only-in-overweight-or-obese-patients 2024-12-31T14:06:22+00:00 weekly 0.7 https://trial.medpath.com/news/cocrystal-pharma-to-extend-phase-2a-influenza-challenge-study-with-oral-pb2-inhibitor-cc-42344 2024-12-31T13:20:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cocrystal-pharma-to-extend-phase-2a-influenza-challenge-study-with-oral-pb2-inhibitor-cc-42344 2024-12-31T13:20:38+00:00 weekly 0.7 https://trial.medpath.com/news/advancing-precision-medicine-in-esophageal-squamous-cell-carcinoma-using-patient 2024-12-31T13:20:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancing-precision-medicine-in-esophageal-squamous-cell-carcinoma-using-patient 2024-12-31T13:20:07+00:00 weekly 0.7 https://trial.medpath.com/news/daily-hong-kong-stock-market-news-briefing-december-31-tuesday-longport 2024-12-31T13:14:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/daily-hong-kong-stock-market-news-briefing-december-31-tuesday-longport 2024-12-31T13:14:51+00:00 weekly 0.7 https://trial.medpath.com/news/drug-repurposing-breakthroughs-established-medications-show-promise-in-cancer-lyme-disease-and-neurological-disorders 2024-12-31T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drug-repurposing-breakthroughs-established-medications-show-promise-in-cancer-lyme-disease-and-neurological-disorders 2024-12-31T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/managing-the-complex-balance-mpn-treatment-challenges-with-jak-inhibitors 2024-12-31T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/managing-the-complex-balance-mpn-treatment-challenges-with-jak-inhibitors 2024-12-31T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/safety-of-fezolinetant-for-treatment-of-moderate-to-severe-vasomotor-symptoms-due-to-menopause 2024-12-31T11:49:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/safety-of-fezolinetant-for-treatment-of-moderate-to-severe-vasomotor-symptoms-due-to-menopause 2024-12-31T11:49:37+00:00 weekly 0.7 https://trial.medpath.com/news/leerink-reiterates-outperform-rating-on-axsome-stock-amid-fda-uncertainty-for-auvelity 2024-12-31T10:09:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leerink-reiterates-outperform-rating-on-axsome-stock-amid-fda-uncertainty-for-auvelity 2024-12-31T10:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/medicare-part-d-expands-mtm-services-to-include-hiv-aids-coverage-in-2025 2024-12-31T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicare-part-d-expands-mtm-services-to-include-hiv-aids-coverage-in-2025 2024-12-31T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/medmira-reports-first-quarter-results-fy2025-biospace 2024-12-31T05:28:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medmira-reports-first-quarter-results-fy2025-biospace 2024-12-31T05:28:02+00:00 weekly 0.7 https://trial.medpath.com/news/nccn-updates-2024-major-guideline-changes-across-multiple-cancer-types 2024-12-31T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nccn-updates-2024-major-guideline-changes-across-multiple-cancer-types 2024-12-31T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pioneer-in-lymphoma-research-dr-margaret-shipp-recognized-as-2024-giant-of-cancer-care 2024-12-31T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pioneer-in-lymphoma-research-dr-margaret-shipp-recognized-as-2024-giant-of-cancer-care 2024-12-31T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/preliminary-study-of-utilizing-a-patient-derived-tumor-spheroid-model-to-augment-precision-nature 2024-12-31T04:35:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/preliminary-study-of-utilizing-a-patient-derived-tumor-spheroid-model-to-augment-precision-nature 2024-12-31T04:35:36+00:00 weekly 0.7 https://trial.medpath.com/news/galera-therapeutics-completes-acquisition-of-nova-pharmaceuticals 2024-12-31T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/galera-therapeutics-completes-acquisition-of-nova-pharmaceuticals 2024-12-31T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pulmonology-in-2024-ai-integration-air-quality-crisis-and-advancing-lung-care-highlighted-in-annual-review 2024-12-31T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pulmonology-in-2024-ai-integration-air-quality-crisis-and-advancing-lung-care-highlighted-in-annual-review 2024-12-31T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cutia-therapeutics-completes-promising-phase-ii-trials-markets-insider 2024-12-31T02:35:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cutia-therapeutics-completes-promising-phase-ii-trials-markets-insider 2024-12-31T02:35:09+00:00 weekly 0.7 https://trial.medpath.com/news/yuhan-s-lung-cancer-drug-leclaza-secures-european-approval-in-combination-therapy 2024-12-31T02:03:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/yuhan-s-lung-cancer-drug-leclaza-secures-european-approval-in-combination-therapy 2024-12-31T02:03:43+00:00 weekly 0.7 https://trial.medpath.com/news/the-beam-dr-annemarie-shepherd-on-proton-therapy-for-thymic-cancers-napt-celebrates 2024-12-31T01:43:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-beam-dr-annemarie-shepherd-on-proton-therapy-for-thymic-cancers-napt-celebrates 2024-12-31T01:43:18+00:00 weekly 0.7 https://trial.medpath.com/news/continuous-glucose-monitoring-among-adults-with-type-2-diabetes-receiving-noninsulin-or-nature 2024-12-31T01:30:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/continuous-glucose-monitoring-among-adults-with-type-2-diabetes-receiving-noninsulin-or-nature 2024-12-31T01:30:30+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-single-and-double-catheter-intrathecal-drug-delivery-systems-in-nature 2024-12-31T00:16:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-and-safety-of-single-and-double-catheter-intrathecal-drug-delivery-systems-in-nature 2024-12-31T00:16:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-revokes-authorization-of-drug-trump-touted-for-covid-19 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-revokes-authorization-of-drug-trump-touted-for-covid-19 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cerebral-palsy-global-clinical-trials-review-2024-clinical-trials-by-region-country-trial-status-trial-phase-sponsor-type-and-end-point-status 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cerebral-palsy-global-clinical-trials-review-2024-clinical-trials-by-region-country-trial-status-trial-phase-sponsor-type-and-end-point-status 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xbrane-resubmits-ranibizumab-biosimilar-bla-to-fda-following-complete-response-letter 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xbrane-resubmits-ranibizumab-biosimilar-bla-to-fda-following-complete-response-letter 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-announces-findings-from-phase-2-keyvibe-002-trial-evaluating-an 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-announces-findings-from-phase-2-keyvibe-002-trial-evaluating-an 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/optima-trial-explores-predictive-test-for-chemotherapy-in-breast-cancer-treatment 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/optima-trial-explores-predictive-test-for-chemotherapy-in-breast-cancer-treatment 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-rejects-sotagliflozin-for-type-1-diabetes-with-ckd-following-negative-advisory-review 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-rejects-sotagliflozin-for-type-1-diabetes-with-ckd-following-negative-advisory-review 2024-12-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adc-therapeutics-announces-completion-of-enrollment-of-phase-3-confirmatory-clinical 2024-12-30T22:00:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adc-therapeutics-announces-completion-of-enrollment-of-phase-3-confirmatory-clinical 2024-12-30T22:00:15+00:00 weekly 0.7 https://trial.medpath.com/news/agios-pharmaceuticals-advances-tebapivat-for-sickle-cell-disease-and-hemolytic-anemias 2024-12-30T21:59:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/agios-pharmaceuticals-advances-tebapivat-for-sickle-cell-disease-and-hemolytic-anemias 2024-12-30T21:59:35+00:00 weekly 0.7 https://trial.medpath.com/news/nvp-healthcare-advances-oral-treatment-nvp-1805r2-for-cardiovascular-disorders 2024-12-30T21:59:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nvp-healthcare-advances-oral-treatment-nvp-1805r2-for-cardiovascular-disorders 2024-12-30T21:59:22+00:00 weekly 0.7 https://trial.medpath.com/news/taiho-pharmaceutical-advances-tas-0728-a-novel-her2-her3-inhibitor-for-multiple-solid-tumors 2024-12-30T21:57:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/taiho-pharmaceutical-advances-tas-0728-a-novel-her2-her3-inhibitor-for-multiple-solid-tumors 2024-12-30T21:57:43+00:00 weekly 0.7 https://trial.medpath.com/news/immedica-acquires-marinus-pharmaceuticals-for-151m-expanding-rare-disease-portfolio-with-ztalmy 2024-12-30T21:44:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immedica-acquires-marinus-pharmaceuticals-for-151m-expanding-rare-disease-portfolio-with-ztalmy 2024-12-30T21:44:39+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-priority-review-to-verastem-s-breakthrough-ovarian-cancer-treatment-vstm 2024-12-30T21:37:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-priority-review-to-verastem-s-breakthrough-ovarian-cancer-treatment-vstm 2024-12-30T21:37:53+00:00 weekly 0.7 https://trial.medpath.com/news/bria-imt-cancer-vaccine-shows-efficacy-tolerability-in-advanced-breast-cancer 2024-12-30T21:13:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bria-imt-cancer-vaccine-shows-efficacy-tolerability-in-advanced-breast-cancer 2024-12-30T21:13:23+00:00 weekly 0.7 https://trial.medpath.com/news/t-dxd-plus-pembrolizumab-elicits-responses-in-io-naive-her2-expressing-or-mutant-nsclc 2024-12-30T21:06:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/t-dxd-plus-pembrolizumab-elicits-responses-in-io-naive-her2-expressing-or-mutant-nsclc 2024-12-30T21:06:29+00:00 weekly 0.7 https://trial.medpath.com/news/novel-car-t-cell-therapy-trial-advances-to-third-cohort-in-ovarian-cancer 2024-12-30T20:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-car-t-cell-therapy-trial-advances-to-third-cohort-in-ovarian-cancer 2024-12-30T20:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kymera-s-stat3-degrader-kt-333-shows-promise-across-multiple-lymphomas-and-solid-tumors 2024-12-30T19:54:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kymera-s-stat3-degrader-kt-333-shows-promise-across-multiple-lymphomas-and-solid-tumors 2024-12-30T19:54:15+00:00 weekly 0.7 https://trial.medpath.com/news/incyte-s-alk2-inhibitor-zilurgisertib-fumarate-shows-promise-across-multiple-hematologic-disorders 2024-12-30T19:49:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/incyte-s-alk2-inhibitor-zilurgisertib-fumarate-shows-promise-across-multiple-hematologic-disorders 2024-12-30T19:49:04+00:00 weekly 0.7 https://trial.medpath.com/news/november-s-phase-iii-successes-syros-cassava-tumble-on-misses-bioworld 2024-12-30T19:35:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/november-s-phase-iii-successes-syros-cassava-tumble-on-misses-bioworld 2024-12-30T19:35:11+00:00 weekly 0.7 https://trial.medpath.com/news/d-boral-capital-served-as-exclusive-placement-agent-to-fibrobiologics-inc-nasdaq 2024-12-30T19:28:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/d-boral-capital-served-as-exclusive-placement-agent-to-fibrobiologics-inc-nasdaq 2024-12-30T19:28:22+00:00 weekly 0.7 https://trial.medpath.com/news/lumisystem-in-lumpectomy-may-reduce-or-omit-radiation-in-breast-cancer 2024-12-30T19:13:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lumisystem-in-lumpectomy-may-reduce-or-omit-radiation-in-breast-cancer 2024-12-30T19:13:32+00:00 weekly 0.7 https://trial.medpath.com/news/addition-of-pembrolizumab-to-chemo-improves-survival-in-cervical-cancer 2024-12-30T19:10:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/addition-of-pembrolizumab-to-chemo-improves-survival-in-cervical-cancer 2024-12-30T19:10:56+00:00 weekly 0.7 https://trial.medpath.com/news/takeda-s-oral-tyk2-inhibitor-zasocitinib-advances-development-for-multiple-autoimmune-conditions 2024-12-30T18:44:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/takeda-s-oral-tyk2-inhibitor-zasocitinib-advances-development-for-multiple-autoimmune-conditions 2024-12-30T18:44:38+00:00 weekly 0.7 https://trial.medpath.com/news/innocare-s-orelabrutinib-shows-promise-in-treating-primary-immune-thrombocytopenia 2024-12-30T18:42:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innocare-s-orelabrutinib-shows-promise-in-treating-primary-immune-thrombocytopenia 2024-12-30T18:42:55+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-anti-pd1-immunotherapy-for-surgically-accessible-recurrent-glioblastoma-nature 2024-12-30T18:38:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-anti-pd1-immunotherapy-for-surgically-accessible-recurrent-glioblastoma-nature 2024-12-30T18:38:17+00:00 weekly 0.7 https://trial.medpath.com/news/kala-bio-announces-10750000-private-placement-biospace 2024-12-30T18:16:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kala-bio-announces-10750000-private-placement-biospace 2024-12-30T18:16:18+00:00 weekly 0.7 https://trial.medpath.com/news/behavioral-intervention-decreases-how-much-pain-affects-daily-activities-in-people-with 2024-12-30T17:51:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/behavioral-intervention-decreases-how-much-pain-affects-daily-activities-in-people-with 2024-12-30T17:51:43+00:00 weekly 0.7 https://trial.medpath.com/news/psca-targeted-bpx-601-car-t-cells-with-pharmacological-activation-by-rimiducid-in 2024-12-30T17:38:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psca-targeted-bpx-601-car-t-cells-with-pharmacological-activation-by-rimiducid-in 2024-12-30T17:38:03+00:00 weekly 0.7 https://trial.medpath.com/news/trivalent-recombinant-protein-vaccine-induces-cross-neutralization-against-xbb-lineage-and 2024-12-30T17:20:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trivalent-recombinant-protein-vaccine-induces-cross-neutralization-against-xbb-lineage-and 2024-12-30T17:20:45+00:00 weekly 0.7 https://trial.medpath.com/news/nos-inhibition-sensitizes-metaplastic-breast-cancer-to-pi3k-inhibition-and-taxane-therapy-via 2024-12-30T17:10:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nos-inhibition-sensitizes-metaplastic-breast-cancer-to-pi3k-inhibition-and-taxane-therapy-via 2024-12-30T17:10:53+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-says-new-drug-helps-children-with-rare-spinal-condition 2024-12-30T17:01:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-says-new-drug-helps-children-with-rare-spinal-condition 2024-12-30T17:01:42+00:00 weekly 0.7 https://trial.medpath.com/news/phaxiam-therapeutics-presents-clinical-data-of-the-phagodair-pilot-study-with-results 2024-12-30T16:53:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phaxiam-therapeutics-presents-clinical-data-of-the-phagodair-pilot-study-with-results 2024-12-30T16:53:17+00:00 weekly 0.7 https://trial.medpath.com/news/top-10-als-news-stories-of-2024 2024-12-30T16:23:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-10-als-news-stories-of-2024 2024-12-30T16:23:14+00:00 weekly 0.7 https://trial.medpath.com/news/top-10-news-stories-of-2024-on-rare-disease-angioedema 2024-12-30T16:17:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-10-news-stories-of-2024-on-rare-disease-angioedema 2024-12-30T16:17:37+00:00 weekly 0.7 https://trial.medpath.com/news/relative-effectiveness-of-antidepressant-treatments-in-treatment-resistant-depression-nature 2024-12-30T14:41:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/relative-effectiveness-of-antidepressant-treatments-in-treatment-resistant-depression-nature 2024-12-30T14:41:10+00:00 weekly 0.7 https://trial.medpath.com/news/nrx-pharmaceuticals-inc-nasdaq-nrxp-files-initial-section-of-u-s-new-drug 2024-12-30T14:19:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nrx-pharmaceuticals-inc-nasdaq-nrxp-files-initial-section-of-u-s-new-drug 2024-12-30T14:19:26+00:00 weekly 0.7 https://trial.medpath.com/news/radiopharm-announces-strategic-co-development-partnership-with-lantheus-for-australia 2024-12-30T13:12:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radiopharm-announces-strategic-co-development-partnership-with-lantheus-for-australia 2024-12-30T13:12:55+00:00 weekly 0.7 https://trial.medpath.com/news/determining-suitable-radioligand-therapy-use-in-neuroendocrine-tumors 2024-12-30T13:03:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/determining-suitable-radioligand-therapy-use-in-neuroendocrine-tumors 2024-12-30T13:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/handok-secures-approval-for-itp-treatment-doptelet-kbr 2024-12-30T13:02:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/handok-secures-approval-for-itp-treatment-doptelet-kbr 2024-12-30T13:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/accuracy-of-esat6-cfp10-skin-test-compared-with-tuberculin-skin-test-in-a-healthy-population 2024-12-30T12:40:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/accuracy-of-esat6-cfp10-skin-test-compared-with-tuberculin-skin-test-in-a-healthy-population 2024-12-30T12:40:05+00:00 weekly 0.7 https://trial.medpath.com/news/axsome-s-alzheimer-s-drug-shows-promise-in-trials-by-investing-com 2024-12-30T12:27:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/axsome-s-alzheimer-s-drug-shows-promise-in-trials-by-investing-com 2024-12-30T12:27:16+00:00 weekly 0.7 https://trial.medpath.com/news/cspc-pharmaceutical-group-limited-s-leuprorelin-extended-release-injection-obtains 2024-12-30T12:23:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cspc-pharmaceutical-group-limited-s-leuprorelin-extended-release-injection-obtains 2024-12-30T12:23:25+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-priority-review-to-precigen-s-prgn-2012-for-recurrent-respiratory-papillomatosis 2024-12-30T12:15:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-priority-review-to-precigen-s-prgn-2012-for-recurrent-respiratory-papillomatosis 2024-12-30T12:15:19+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-ingelheim-advances-vicadrostat-development-for-chronic-kidney-disease-and-heart-failure 2024-12-30T11:38:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-ingelheim-advances-vicadrostat-development-for-chronic-kidney-disease-and-heart-failure 2024-12-30T11:38:24+00:00 weekly 0.7 https://trial.medpath.com/news/nevada-king-gold-reports-significant-discoveries-and-outlines-ambitious-2025-drill-program-at-atlanta-gold-project 2024-12-30T11:33:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nevada-king-gold-reports-significant-discoveries-and-outlines-ambitious-2025-drill-program-at-atlanta-gold-project 2024-12-30T11:33:32+00:00 weekly 0.7 https://trial.medpath.com/news/engaging-fathers-to-be-a-pilot-study-on-the-adaptation-and-programme-experience-of 2024-12-30T10:30:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/engaging-fathers-to-be-a-pilot-study-on-the-adaptation-and-programme-experience-of 2024-12-30T10:30:39+00:00 weekly 0.7 https://trial.medpath.com/news/leyden-labs-advances-novel-broad-spectrum-nasal-antibody-cr-9114-against-multiple-influenza-strains 2024-12-30T10:24:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leyden-labs-advances-novel-broad-spectrum-nasal-antibody-cr-9114-against-multiple-influenza-strains 2024-12-30T10:24:47+00:00 weekly 0.7 https://trial.medpath.com/news/innovation-pharmaceuticals-brilacidin-shows-promise-across-multiple-therapeutic-areas 2024-12-30T10:19:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovation-pharmaceuticals-brilacidin-shows-promise-across-multiple-therapeutic-areas 2024-12-30T10:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/new-schizophrenia-drug-may-have-milder-side-effects-word-in-black 2024-12-30T10:14:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-schizophrenia-drug-may-have-milder-side-effects-word-in-black 2024-12-30T10:14:28+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-tecentriq-atezolizumab-expands-development-program-into-squamous-non-small-cell-lung-cancer 2024-12-30T10:08:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-s-tecentriq-atezolizumab-expands-development-program-into-squamous-non-small-cell-lung-cancer 2024-12-30T10:08:59+00:00 weekly 0.7 https://trial.medpath.com/news/the-efficacy-of-longer-term-lebrikizumab-treatment-in-patients-with-moderate-to-severe-pubmed 2024-12-30T09:48:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-efficacy-of-longer-term-lebrikizumab-treatment-in-patients-with-moderate-to-severe-pubmed 2024-12-30T09:48:54+00:00 weekly 0.7 https://trial.medpath.com/news/mayo-clinic-s-e-visit-billing-program-shows-8-8-reduction-in-patient-portal-messages 2024-12-30T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mayo-clinic-s-e-visit-billing-program-shows-8-8-reduction-in-patient-portal-messages 2024-12-30T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2024-marks-a-turning-point-in-weight-loss-for-floridians-with-anti-obesity-medications 2024-12-30T08:16:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024-marks-a-turning-point-in-weight-loss-for-floridians-with-anti-obesity-medications 2024-12-30T08:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-approves-rybrevant-r-amivantamab-in-globenewswire 2024-12-30T08:01:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-commission-approves-rybrevant-r-amivantamab-in-globenewswire 2024-12-30T08:01:42+00:00 weekly 0.7 https://trial.medpath.com/news/top-10-healthcare-news-in-2024-7-yuhan-s-leclaza-makes-us-entry-to-become-a-global 2024-12-30T07:42:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-10-healthcare-news-in-2024-7-yuhan-s-leclaza-makes-us-entry-to-become-a-global 2024-12-30T07:42:13+00:00 weekly 0.7 https://trial.medpath.com/news/participation-and-compliance-in-a-multimodal-prehabilitation-program-f-ppa 2024-12-30T07:29:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/participation-and-compliance-in-a-multimodal-prehabilitation-program-f-ppa 2024-12-30T07:29:42+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-significant-gap-between-pah-patient-and-physician-symptom-assessment 2024-12-30T06:19:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-significant-gap-between-pah-patient-and-physician-symptom-assessment 2024-12-30T06:19:00+00:00 weekly 0.7 https://trial.medpath.com/news/mayo-clinic-s-dr-rafael-fonseca-pioneering-multiple-myeloma-research-and-treatment-revolution 2024-12-30T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mayo-clinic-s-dr-rafael-fonseca-pioneering-multiple-myeloma-research-and-treatment-revolution 2024-12-30T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/critical-drug-shortages-persist-in-2024-despite-overall-decline-in-supply-disruptions 2024-12-30T05:57:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/critical-drug-shortages-persist-in-2024-despite-overall-decline-in-supply-disruptions 2024-12-30T05:57:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-intrathecal-onasemnogene-abeparvovec-phase-iii-globenewswire 2024-12-30T05:46:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-intrathecal-onasemnogene-abeparvovec-phase-iii-globenewswire 2024-12-30T05:46:02+00:00 weekly 0.7 https://trial.medpath.com/news/key-research-advances-in-mds-treatment-and-risk-assessment-2024-s-most-impactful-studies 2024-12-30T05:44:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/key-research-advances-in-mds-treatment-and-risk-assessment-2024-s-most-impactful-studies 2024-12-30T05:44:00+00:00 weekly 0.7 https://trial.medpath.com/news/zorifer-poised-to-fill-critical-gap-in-treatment-of-advanced-nsclc-with-cns-metastases-in 2024-12-30T05:34:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zorifer-poised-to-fill-critical-gap-in-treatment-of-advanced-nsclc-with-cns-metastases-in 2024-12-30T05:34:50+00:00 weekly 0.7 https://trial.medpath.com/news/ruxolitinib-cream-shows-promise-in-pediatric-atopic-dermatitis-and-vitiligo-treatment-spd-2024-findings 2024-12-30T05:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ruxolitinib-cream-shows-promise-in-pediatric-atopic-dermatitis-and-vitiligo-treatment-spd-2024-findings 2024-12-30T05:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/340b-drug-program-faces-scrutiny-over-hospital-markups-and-transparency-issues-in-cancer-care 2024-12-30T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/340b-drug-program-faces-scrutiny-over-hospital-markups-and-transparency-issues-in-cancer-care 2024-12-30T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abion-s-c-met-targeted-anticancer-drug-phase-2-change-approved-by-fda-lazertinib 2024-12-30T04:47:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abion-s-c-met-targeted-anticancer-drug-phase-2-change-approved-by-fda-lazertinib 2024-12-30T04:47:24+00:00 weekly 0.7 https://trial.medpath.com/news/vincerx-pharma-enters-into-a-binding-term-sheet-for-a-strategic-merger-with-oqory-inc 2024-12-30T04:40:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vincerx-pharma-enters-into-a-binding-term-sheet-for-a-strategic-merger-with-oqory-inc 2024-12-30T04:40:10+00:00 weekly 0.7 https://trial.medpath.com/news/vor-bio-announces-55-6-million-private-placement-biospace 2024-12-30T04:40:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vor-bio-announces-55-6-million-private-placement-biospace 2024-12-30T04:40:05+00:00 weekly 0.7 https://trial.medpath.com/news/yoltech-therapeutics-granted-fda-orphan-drug-and-rare-pediatric-disease-designations 2024-12-30T04:39:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/yoltech-therapeutics-granted-fda-orphan-drug-and-rare-pediatric-disease-designations 2024-12-30T04:39:58+00:00 weekly 0.7 https://trial.medpath.com/news/immune-biomarkers-show-promise-in-guiding-tnbc-treatment-decisions 2024-12-30T04:33:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immune-biomarkers-show-promise-in-guiding-tnbc-treatment-decisions 2024-12-30T04:33:02+00:00 weekly 0.7 https://trial.medpath.com/news/carsgen-reports-positive-trial-results-for-cancer-therapy-markets-insider 2024-12-30T03:22:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/carsgen-reports-positive-trial-results-for-cancer-therapy-markets-insider 2024-12-30T03:22:49+00:00 weekly 0.7 https://trial.medpath.com/news/digital-biomarkers-revolutionize-respiratory-disease-management-new-hope-for-copd-and-asthma-patients 2024-12-30T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-biomarkers-revolutionize-respiratory-disease-management-new-hope-for-copd-and-asthma-patients 2024-12-30T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kintor-s-phase-iii-trial-milestone-for-hair-loss-treatment-tipranks-com 2024-12-30T00:12:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kintor-s-phase-iii-trial-milestone-for-hair-loss-treatment-tipranks-com 2024-12-30T00:12:32+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-s-2024-pillars-of-progress-top-news-in-ophthalmology 2024-12-30T00:00:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cgtlive-s-2024-pillars-of-progress-top-news-in-ophthalmology 2024-12-30T00:00:34+00:00 weekly 0.7 https://trial.medpath.com/news/exscientia-claims-world-first-as-ai-created-drug-enters-clinic 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exscientia-claims-world-first-as-ai-created-drug-enters-clinic 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/covid-19-pipeline-insights-clinical-trials-treatment-drugs-and-companies-2024-updated 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/covid-19-pipeline-insights-clinical-trials-treatment-drugs-and-companies-2024-updated 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-expands-car-t-therapy-kymriah-s-use-in-europe-outpacing-gilead-s-rival 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-expands-car-t-therapy-kymriah-s-use-in-europe-outpacing-gilead-s-rival 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthroughs-in-bladder-cancer-treatment-highlighted-in-2024 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthroughs-in-bladder-cancer-treatment-highlighted-in-2024 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/slrn-stock-touches-52-week-low-at-3-06-amid-market-challenges-by-investing-com 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/slrn-stock-touches-52-week-low-at-3-06-amid-market-challenges-by-investing-com 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/italian-multicenter-trial-evaluates-lifestyle-intervention-for-long-term-lymphoma-survivors 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/italian-multicenter-trial-evaluates-lifestyle-intervention-for-long-term-lymphoma-survivors 2024-12-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neurologylive-r-year-in-review-2024-top-stories-in-multiple-sclerosis 2024-12-29T23:09:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurologylive-r-year-in-review-2024-top-stories-in-multiple-sclerosis 2024-12-29T23:09:08+00:00 weekly 0.7 https://trial.medpath.com/news/new-study-highlights-ai-s-role-in-stimulating-thought-caliber-az 2024-12-29T22:27:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-study-highlights-ai-s-role-in-stimulating-thought-caliber-az 2024-12-29T22:27:15+00:00 weekly 0.7 https://trial.medpath.com/news/telix-files-tlx250-cdx-zircaix-r-bla-for-kidney-cancer-imaging-globenewswire 2024-12-29T21:59:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/telix-files-tlx250-cdx-zircaix-r-bla-for-kidney-cancer-imaging-globenewswire 2024-12-29T21:59:58+00:00 weekly 0.7 https://trial.medpath.com/news/cel-sci-secures-5-million-in-public-offering-to-advance-multikine-cancer-immunotherapy 2024-12-29T19:49:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cel-sci-secures-5-million-in-public-offering-to-advance-multikine-cancer-immunotherapy 2024-12-29T19:49:35+00:00 weekly 0.7 https://trial.medpath.com/news/jaaf-gtex-drive-sl-s-textile-innovation-and-competitiveness-daily-mirror 2024-12-29T19:21:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jaaf-gtex-drive-sl-s-textile-innovation-and-competitiveness-daily-mirror 2024-12-29T19:21:16+00:00 weekly 0.7 https://trial.medpath.com/news/breakthroughs-and-battles-in-health-new-approvals-lawsuits-and-discoveries 2024-12-29T19:00:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthroughs-and-battles-in-health-new-approvals-lawsuits-and-discoveries 2024-12-29T19:00:06+00:00 weekly 0.7 https://trial.medpath.com/news/top-10-kidney-cancer-stories-in-2024 2024-12-29T17:08:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-10-kidney-cancer-stories-in-2024 2024-12-29T17:08:58+00:00 weekly 0.7 https://trial.medpath.com/news/2024-veterinary-news-in-review-3-dvm360 2024-12-29T16:08:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024-veterinary-news-in-review-3-dvm360 2024-12-29T16:08:27+00:00 weekly 0.7 https://trial.medpath.com/news/second-line-lenvatinib-shows-promising-pfs-in-advanced-hcc-oncology-nursing-news 2024-12-29T15:06:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/second-line-lenvatinib-shows-promising-pfs-in-advanced-hcc-oncology-nursing-news 2024-12-29T15:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/ivonescimab-chemo-combo-yields-positive-efficacy-and-safety-results-in-tnbc 2024-12-29T15:03:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ivonescimab-chemo-combo-yields-positive-efficacy-and-safety-results-in-tnbc 2024-12-29T15:03:08+00:00 weekly 0.7 https://trial.medpath.com/news/a-randomized-trial-of-low-dose-thrombolysis-ultrasound-assisted-thrombolysis-or-heparin 2024-12-29T15:00:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-randomized-trial-of-low-dose-thrombolysis-ultrasound-assisted-thrombolysis-or-heparin 2024-12-29T15:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/have-the-new-pulmonary-hypertension-drugs-changed-the-game-medpage-today 2024-12-29T14:19:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/have-the-new-pulmonary-hypertension-drugs-changed-the-game-medpage-today 2024-12-29T14:19:34+00:00 weekly 0.7 https://trial.medpath.com/news/neurologylive-r-year-in-review-2024-top-stories-in-movement-disorders 2024-12-29T13:55:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurologylive-r-year-in-review-2024-top-stories-in-movement-disorders 2024-12-29T13:55:31+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-biosciences-secures-exclusive-license-for-novel-cancer-treatment-gurufocus 2024-12-29T12:38:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ideaya-biosciences-secures-exclusive-license-for-novel-cancer-treatment-gurufocus 2024-12-29T12:38:47+00:00 weekly 0.7 https://trial.medpath.com/news/io-biotech-faces-possible-nasdaq-delisting-over-low-stock-price 2024-12-29T12:24:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/io-biotech-faces-possible-nasdaq-delisting-over-low-stock-price 2024-12-29T12:24:00+00:00 weekly 0.7 https://trial.medpath.com/news/aoh1996-targets-mitochondrial-dynamics-and-metabolism-in-leukemic-stem-cells-via 2024-12-29T10:52:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aoh1996-targets-mitochondrial-dynamics-and-metabolism-in-leukemic-stem-cells-via 2024-12-29T10:52:18+00:00 weekly 0.7 https://trial.medpath.com/news/short-interest-in-adlai-nortye-ltd-nasdaq-anl-increases-by-28-0-marketbeat 2024-12-29T10:44:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/short-interest-in-adlai-nortye-ltd-nasdaq-anl-increases-by-28-0-marketbeat 2024-12-29T10:44:04+00:00 weekly 0.7 https://trial.medpath.com/news/bio-path-holdings-advances-clinical-trials-and-secures-4-million-in-funding-citybuzz 2024-12-29T10:04:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bio-path-holdings-advances-clinical-trials-and-secures-4-million-in-funding-citybuzz 2024-12-29T10:04:25+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approvals-and-treatment-advances-mark-major-progress-in-pah-management-for-2024 2024-12-29T09:27:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approvals-and-treatment-advances-mark-major-progress-in-pah-management-for-2024 2024-12-29T09:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/early-detection-through-symptom-based-testing-shows-promise-in-ovarian-cancer-diagnosis 2024-12-29T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-detection-through-symptom-based-testing-shows-promise-in-ovarian-cancer-diagnosis 2024-12-29T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/leading-mds-expert-dr-garcia-manero-reflects-on-25-years-of-mentorship-and-innovation-at-md-anderson 2024-12-29T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leading-mds-expert-dr-garcia-manero-reflects-on-25-years-of-mentorship-and-innovation-at-md-anderson 2024-12-29T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/telehealth-proves-vital-for-rare-disease-management-post-pandemic-breaking-healthcare-access-barriers 2024-12-29T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/telehealth-proves-vital-for-rare-disease-management-post-pandemic-breaking-healthcare-access-barriers 2024-12-29T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/expert-insights-keys-to-successfully-transitioning-from-hematology-oncology-fellow-to-attending-physician 2024-12-29T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expert-insights-keys-to-successfully-transitioning-from-hematology-oncology-fellow-to-attending-physician 2024-12-29T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dermatology-times-2024-in-review-hidradenitis-suppurativa 2024-12-29T02:09:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dermatology-times-2024-in-review-hidradenitis-suppurativa 2024-12-29T02:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/biocardia-s-short-interest-declines-19-5-as-analysts-maintain-bullish-outlook 2024-12-28T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biocardia-s-short-interest-declines-19-5-as-analysts-maintain-bullish-outlook 2024-12-28T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-nk-cell-therapy-myj-1633-shows-promise-for-multiple-cancer-types-including-her2-breast-cancer 2024-12-28T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-nk-cell-therapy-myj-1633-shows-promise-for-multiple-cancer-types-including-her2-breast-cancer 2024-12-28T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/top-10-prostate-cancer-articles-and-videos-of-2024-urology-times 2024-12-28T23:08:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-10-prostate-cancer-articles-and-videos-of-2024-urology-times 2024-12-28T23:08:57+00:00 weekly 0.7 https://trial.medpath.com/news/neurologylive-r-year-in-review-2024-top-stories-in-headache-and-migraine 2024-12-28T22:09:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurologylive-r-year-in-review-2024-top-stories-in-headache-and-migraine 2024-12-28T22:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/new-pill-that-slows-down-alzheimer-s-being-considered-for-use-by-nhs-daily-express 2024-12-28T21:36:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-pill-that-slows-down-alzheimer-s-being-considered-for-use-by-nhs-daily-express 2024-12-28T21:36:09+00:00 weekly 0.7 https://trial.medpath.com/news/2024-brings-change-new-hope-for-nonhormonal-management-of-menopause-hcplive 2024-12-28T19:37:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024-brings-change-new-hope-for-nonhormonal-management-of-menopause-hcplive 2024-12-28T19:37:12+00:00 weekly 0.7 https://trial.medpath.com/news/contagion-s-2024-top-stories-c-difficile 2024-12-28T19:05:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/contagion-s-2024-top-stories-c-difficile 2024-12-28T19:05:48+00:00 weekly 0.7 https://trial.medpath.com/news/iqvia-gets-cdsco-panel-nod-to-conduct-phase-iii-clinical-study-of-lumateperone 2024-12-28T17:47:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iqvia-gets-cdsco-panel-nod-to-conduct-phase-iii-clinical-study-of-lumateperone 2024-12-28T17:47:57+00:00 weekly 0.7 https://trial.medpath.com/news/zanidatamab-evorpacept-combo-yields-promising-activity-in-her2-breast-cancer 2024-12-28T17:08:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zanidatamab-evorpacept-combo-yields-promising-activity-in-her2-breast-cancer 2024-12-28T17:08:07+00:00 weekly 0.7 https://trial.medpath.com/news/china-developed-eye-cancer-drug-granted-fda-orphan-drug-designation 2024-12-28T16:38:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/china-developed-eye-cancer-drug-granted-fda-orphan-drug-designation 2024-12-28T16:38:23+00:00 weekly 0.7 https://trial.medpath.com/news/who-wants-a-pig-organ-patients-sick-and-tired-of-waiting-years-for-a-transplant-health 2024-12-28T16:16:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/who-wants-a-pig-organ-patients-sick-and-tired-of-waiting-years-for-a-transplant-health 2024-12-28T16:16:28+00:00 weekly 0.7 https://trial.medpath.com/news/top-endovascular-news-of-2024-tctmd-com 2024-12-28T14:39:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-endovascular-news-of-2024-tctmd-com 2024-12-28T14:39:24+00:00 weekly 0.7 https://trial.medpath.com/news/cruise-ships-and-norovirus-don-t-mix-vax-before-travel 2024-12-28T14:30:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cruise-ships-and-norovirus-don-t-mix-vax-before-travel 2024-12-28T14:30:42+00:00 weekly 0.7 https://trial.medpath.com/news/faricimab-lacks-proof-of-added-benefit-over-comparator-therapies-for-macular-edema 2024-12-28T14:05:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/faricimab-lacks-proof-of-added-benefit-over-comparator-therapies-for-macular-edema 2024-12-28T14:05:07+00:00 weekly 0.7 https://trial.medpath.com/news/vaxart-secures-additional-4-6-m-for-covid-19-pill-vaccine-trial-investing-com-nigeria 2024-12-28T13:36:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vaxart-secures-additional-4-6-m-for-covid-19-pill-vaccine-trial-investing-com-nigeria 2024-12-28T13:36:26+00:00 weekly 0.7 https://trial.medpath.com/news/probiotic-treatment-induces-changes-in-intestinal-microbiota-but-does-not-alter-scfa-levels 2024-12-28T13:12:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/probiotic-treatment-induces-changes-in-intestinal-microbiota-but-does-not-alter-scfa-levels 2024-12-28T13:12:03+00:00 weekly 0.7 https://trial.medpath.com/news/fmba-has-begun-clinical-trials-of-a-vaccine-against-five-serotypes-of-meningococcus-news 2024-12-28T12:38:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fmba-has-begun-clinical-trials-of-a-vaccine-against-five-serotypes-of-meningococcus-news 2024-12-28T12:38:30+00:00 weekly 0.7 https://trial.medpath.com/news/earliest-clinical-trial-for-vco-to-end-in-december-next-year-for-avigan-doh-abs-cbn 2024-12-28T11:57:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/earliest-clinical-trial-for-vco-to-end-in-december-next-year-for-avigan-doh-abs-cbn 2024-12-28T11:57:06+00:00 weekly 0.7 https://trial.medpath.com/news/evaluation-of-vascular-photobiomodulation-for-orofacial-pain-and-tension-type-headache 2024-12-28T11:50:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluation-of-vascular-photobiomodulation-for-orofacial-pain-and-tension-type-headache 2024-12-28T11:50:51+00:00 weekly 0.7 https://trial.medpath.com/news/top-10-genitourinary-cancer-advances-in-2024-targeted-oncology 2024-12-28T10:06:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-10-genitourinary-cancer-advances-in-2024-targeted-oncology 2024-12-28T10:06:36+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-chronic-hand-eczema-treatment-tofacitinib-shows-promising-results 2024-12-28T09:17:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-chronic-hand-eczema-treatment-tofacitinib-shows-promising-results 2024-12-28T09:17:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-subcutaneous-nivolumab-in-advanced-or-metastatic-solid-tumors-onclive 2024-12-28T08:49:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-subcutaneous-nivolumab-in-advanced-or-metastatic-solid-tumors-onclive 2024-12-28T08:49:37+00:00 weekly 0.7 https://trial.medpath.com/news/clinically-validated-classification-of-chronic-wounds-method-with-memristor-based-cellular 2024-12-28T08:26:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinically-validated-classification-of-chronic-wounds-method-with-memristor-based-cellular 2024-12-28T08:26:40+00:00 weekly 0.7 https://trial.medpath.com/news/headway-in-hepatology-resmetirom-s-historic-fda-approval-what-s-next-in-mash 2024-12-28T07:43:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/headway-in-hepatology-resmetirom-s-historic-fda-approval-what-s-next-in-mash 2024-12-28T07:43:35+00:00 weekly 0.7 https://trial.medpath.com/news/2024-rsv-vaccination-guidelines-strengthen-recommendations-for-adults-75-and-older 2024-12-28T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024-rsv-vaccination-guidelines-strengthen-recommendations-for-adults-75-and-older 2024-12-28T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dr-carol-aghajanian-pioneering-patient-centric-innovation-in-gynecologic-cancer-treatment 2024-12-28T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-carol-aghajanian-pioneering-patient-centric-innovation-in-gynecologic-cancer-treatment 2024-12-28T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-powered-tool-predicts-treatment-outcomes-for-brain-metastases-following-radiosurgery 2024-12-28T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-powered-tool-predicts-treatment-outcomes-for-brain-metastases-following-radiosurgery 2024-12-28T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/inside-the-battle-for-fda-approval-of-mdma-therapy-big-think 2024-12-28T03:31:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inside-the-battle-for-fda-approval-of-mdma-therapy-big-think 2024-12-28T03:31:22+00:00 weekly 0.7 https://trial.medpath.com/news/mezigdomide-combinations-show-promise-in-multiple-myeloma-medpage-today 2024-12-28T03:10:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mezigdomide-combinations-show-promise-in-multiple-myeloma-medpage-today 2024-12-28T03:10:26+00:00 weekly 0.7 https://trial.medpath.com/news/top-5-articles-in-2024-for-oncology-apps-and-nurses 2024-12-28T03:04:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-5-articles-in-2024-for-oncology-apps-and-nurses 2024-12-28T03:04:04+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-gap-in-community-practice-training-for-hematology-oncology-fellows 2024-12-28T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-gap-in-community-practice-training-for-hematology-oncology-fellows 2024-12-28T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/greg-forlenza-md-discusses-clver-trial-among-newly-diagnosed-type-1-diabetes-patients 2024-12-28T02:37:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/greg-forlenza-md-discusses-clver-trial-among-newly-diagnosed-type-1-diabetes-patients 2024-12-28T02:37:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-roundup-december-27-2024-pr-newswire 2024-12-28T02:32:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-roundup-december-27-2024-pr-newswire 2024-12-28T02:32:53+00:00 weekly 0.7 https://trial.medpath.com/news/frontiers-comparative-efficacy-of-different-drugs-in-acute-heart-failure-with-renal-dysfunction 2024-12-28T02:02:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/frontiers-comparative-efficacy-of-different-drugs-in-acute-heart-failure-with-renal-dysfunction 2024-12-28T02:02:37+00:00 weekly 0.7 https://trial.medpath.com/news/mixed-evidence-on-glp-1-medications-and-suicide-risk-a-2024-safety-analysis-review 2024-12-28T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mixed-evidence-on-glp-1-medications-and-suicide-risk-a-2024-safety-analysis-review 2024-12-28T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/optimizing-the-cumulative-cisplatin-dose-for-concurrent-chemoradiotherapy-beneficiaries 2024-12-28T01:54:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/optimizing-the-cumulative-cisplatin-dose-for-concurrent-chemoradiotherapy-beneficiaries 2024-12-28T01:54:42+00:00 weekly 0.7 https://trial.medpath.com/news/a-randomised-controlled-pilot-trial-protocol-for-patient-led-cognitive-gamified-training-during 2024-12-28T01:35:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-randomised-controlled-pilot-trial-protocol-for-patient-led-cognitive-gamified-training-during 2024-12-28T01:35:18+00:00 weekly 0.7 https://trial.medpath.com/news/eqbmed-broadens-reach-final-four-clinical-trial-sites-of-the-learning-phase-selected 2024-12-28T00:17:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eqbmed-broadens-reach-final-four-clinical-trial-sites-of-the-learning-phase-selected 2024-12-28T00:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-receives-fda-approval-for-cancer-treatment-marketwatch 2024-12-27T23:29:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-squibb-receives-fda-approval-for-cancer-treatment-marketwatch 2024-12-27T23:29:09+00:00 weekly 0.7 https://trial.medpath.com/news/citius-pharmaceuticals-inc-reports-fiscal-full-year-2024-financial-results-and-provides 2024-12-27T22:02:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/citius-pharmaceuticals-inc-reports-fiscal-full-year-2024-financial-results-and-provides 2024-12-27T22:02:15+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-approves-subcutaneous-opdivo-extending-key-bms-franchise-into-2030s 2024-12-27T21:24:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-approves-subcutaneous-opdivo-extending-key-bms-franchise-into-2030s 2024-12-27T21:24:42+00:00 weekly 0.7 https://trial.medpath.com/news/nebraska-medicine-administers-novel-gene-therapy-to-first-hemophilia-patient 2024-12-27T21:09:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nebraska-medicine-administers-novel-gene-therapy-to-first-hemophilia-patient 2024-12-27T21:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/ebola-how-a-vaccine-turned-a-terrifying-virus-into-a-preventable-disease-cnn 2024-12-27T20:26:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ebola-how-a-vaccine-turned-a-terrifying-virus-into-a-preventable-disease-cnn 2024-12-27T20:26:17+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-pembrolizumab-plus-rt-may-enhance-dfs-outcomes-in-sarcomas 2024-12-27T19:07:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-pembrolizumab-plus-rt-may-enhance-dfs-outcomes-in-sarcomas 2024-12-27T19:07:52+00:00 weekly 0.7 https://trial.medpath.com/news/ema-s-chmp-recommends-approval-of-six-new-biosimilars-goodwin-jdsupra 2024-12-27T17:36:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-s-chmp-recommends-approval-of-six-new-biosimilars-goodwin-jdsupra 2024-12-27T17:36:04+00:00 weekly 0.7 https://trial.medpath.com/news/top-5-most-viewed-liver-cancer-content-for-2024 2024-12-27T17:31:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-5-most-viewed-liver-cancer-content-for-2024 2024-12-27T17:31:40+00:00 weekly 0.7 https://trial.medpath.com/news/puma-biotechnology-stock-rises-24-in-3-months-here-s-why-yahoo-finance 2024-12-27T17:20:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/puma-biotechnology-stock-rises-24-in-3-months-here-s-why-yahoo-finance 2024-12-27T17:20:29+00:00 weekly 0.7 https://trial.medpath.com/news/what-awaits-actinium-in-q4 2024-12-27T17:07:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-awaits-actinium-in-q4 2024-12-27T17:07:29+00:00 weekly 0.7 https://trial.medpath.com/news/sino-biopharmaceutical-limited-announces-positive-results-from-phase-iii-study-marketscreener 2024-12-27T16:30:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sino-biopharmaceutical-limited-announces-positive-results-from-phase-iii-study-marketscreener 2024-12-27T16:30:25+00:00 weekly 0.7 https://trial.medpath.com/news/avacta-group-advances-oncology-pipeline-with-novel-therapies-and-ai-collaboration 2024-12-27T16:27:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avacta-group-advances-oncology-pipeline-with-novel-therapies-and-ai-collaboration 2024-12-27T16:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/changes-in-gut-microbiota-after-gastric-cancer-surgery-a-prospective-longitudinal-study 2024-12-27T15:58:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/changes-in-gut-microbiota-after-gastric-cancer-surgery-a-prospective-longitudinal-study 2024-12-27T15:58:52+00:00 weekly 0.7 https://trial.medpath.com/news/5-major-alzheimer-s-discoveries-scientists-made-in-2024-aol-com 2024-12-27T15:48:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/5-major-alzheimer-s-discoveries-scientists-made-in-2024-aol-com 2024-12-27T15:48:29+00:00 weekly 0.7 https://trial.medpath.com/news/ucsd-researchers-clinically-validate-blood-pressure-monitoring-patch 2024-12-27T15:38:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucsd-researchers-clinically-validate-blood-pressure-monitoring-patch 2024-12-27T15:38:06+00:00 weekly 0.7 https://trial.medpath.com/news/top-10-food-allergy-stories-of-2024-healio 2024-12-27T15:18:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-10-food-allergy-stories-of-2024-healio 2024-12-27T15:18:33+00:00 weekly 0.7 https://trial.medpath.com/news/cardiol-therapeutics-sees-insider-buying-from-leadership-team-and-board-members 2024-12-27T15:07:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiol-therapeutics-sees-insider-buying-from-leadership-team-and-board-members 2024-12-27T15:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/decentralized-clinical-trials-are-better-for-the-participants-and-for-the-planet-the-case-study 2024-12-27T14:55:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/decentralized-clinical-trials-are-better-for-the-participants-and-for-the-planet-the-case-study 2024-12-27T14:55:27+00:00 weekly 0.7 https://trial.medpath.com/news/cereno-scientific-has-enrolled-9-additional-patients-in-its-expanded-access-program-cision-news 2024-12-27T14:38:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cereno-scientific-has-enrolled-9-additional-patients-in-its-expanded-access-program-cision-news 2024-12-27T14:38:16+00:00 weekly 0.7 https://trial.medpath.com/news/cbd-may-reduce-alcohol-cravings-in-people-with-aud-study-finds-forbes 2024-12-27T14:01:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cbd-may-reduce-alcohol-cravings-in-people-with-aud-study-finds-forbes 2024-12-27T14:01:48+00:00 weekly 0.7 https://trial.medpath.com/news/painreform-provides-further-update-on-phase-3-clinical-trial-of-prf-110-globenewswire 2024-12-27T13:56:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/painreform-provides-further-update-on-phase-3-clinical-trial-of-prf-110-globenewswire 2024-12-27T13:56:29+00:00 weekly 0.7 https://trial.medpath.com/news/outlook-therapeutics-r-reports-financial-results-for-fiscal-year-2024-and-provides 2024-12-27T13:17:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/outlook-therapeutics-r-reports-financial-results-for-fiscal-year-2024-and-provides 2024-12-27T13:17:41+00:00 weekly 0.7 https://trial.medpath.com/news/top-mesothelioma-and-asbestos-news-in-2024 2024-12-27T12:58:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-mesothelioma-and-asbestos-news-in-2024 2024-12-27T12:58:09+00:00 weekly 0.7 https://trial.medpath.com/news/feasibility-study-and-pilot-rct-on-tourniquet-use-in-total-knee-replacement-surgery 2024-12-27T12:27:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/feasibility-study-and-pilot-rct-on-tourniquet-use-in-total-knee-replacement-surgery 2024-12-27T12:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/in-kids-with-crohn-s-disease-tnf-inhibitors-help-prevent-serious-complications-data-suggests 2024-12-27T12:12:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in-kids-with-crohn-s-disease-tnf-inhibitors-help-prevent-serious-complications-data-suggests 2024-12-27T12:12:45+00:00 weekly 0.7 https://trial.medpath.com/news/chugai-obtains-regulatory-approval-for-lunsumio-for-intravenous-infusion-for-relapsed 2024-12-27T12:05:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chugai-obtains-regulatory-approval-for-lunsumio-for-intravenous-infusion-for-relapsed 2024-12-27T12:05:09+00:00 weekly 0.7 https://trial.medpath.com/news/enrolment-patterns-in-a-randomized-controlled-trial-of-probiotics-in-critically-ill-patients 2024-12-27T11:29:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enrolment-patterns-in-a-randomized-controlled-trial-of-probiotics-in-critically-ill-patients 2024-12-27T11:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-tevimbra-chemotherapy-combination-for-first-line-treatment-of-advanced-esophageal-squamous-cell-carcinoma 2024-12-27T11:10:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-tevimbra-chemotherapy-combination-for-first-line-treatment-of-advanced-esophageal-squamous-cell-carcinoma 2024-12-27T11:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/argenx-announces-approval-of-vyvdura-efgartigimod-alfa-and-hyaluronidase-qvfc-in 2024-12-27T10:23:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/argenx-announces-approval-of-vyvdura-efgartigimod-alfa-and-hyaluronidase-qvfc-in 2024-12-27T10:23:34+00:00 weekly 0.7 https://trial.medpath.com/news/sensorion-announces-completion-of-enrollment-of-the-first-cohort-of-the-audiogene-biospace 2024-12-27T10:19:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sensorion-announces-completion-of-enrollment-of-the-first-cohort-of-the-audiogene-biospace 2024-12-27T10:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/relapsed-multiple-myeloma-clinical-trials-review-2024-globenewswire 2024-12-27T09:36:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/relapsed-multiple-myeloma-clinical-trials-review-2024-globenewswire 2024-12-27T09:36:56+00:00 weekly 0.7 https://trial.medpath.com/news/dengue-fever-global-clinical-trials-review-2024-globenewswire 2024-12-27T09:35:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dengue-fever-global-clinical-trials-review-2024-globenewswire 2024-12-27T09:35:02+00:00 weekly 0.7 https://trial.medpath.com/news/updated-colonoscopy-guidelines-reshape-quality-metrics-as-family-physician-procedures-decline 2024-12-27T09:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/updated-colonoscopy-guidelines-reshape-quality-metrics-as-family-physician-procedures-decline 2024-12-27T09:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/ono-receives-supplemental-approval-of-opdivo-r-in-combination-with-cisplatin-and 2024-12-27T09:11:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ono-receives-supplemental-approval-of-opdivo-r-in-combination-with-cisplatin-and 2024-12-27T09:11:44+00:00 weekly 0.7 https://trial.medpath.com/news/alto-neuroscience-presents-key-data-study-findings-on-alto-300-psychiatric-times 2024-12-27T08:00:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alto-neuroscience-presents-key-data-study-findings-on-alto-300-psychiatric-times 2024-12-27T08:00:34+00:00 weekly 0.7 https://trial.medpath.com/news/novel-ruxolitinib-dosing-strategy-shows-promise-in-managing-anemic-myelofibrosis-patients 2024-12-27T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-ruxolitinib-dosing-strategy-shows-promise-in-managing-anemic-myelofibrosis-patients 2024-12-27T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pioneer-in-genitourinary-oncology-dr-christopher-logothetis-s-journey-from-greece-to-revolutionizing-cancer-care 2024-12-27T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pioneer-in-genitourinary-oncology-dr-christopher-logothetis-s-journey-from-greece-to-revolutionizing-cancer-care 2024-12-27T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-domestic-drug-for-one-type-of-cancer-has-been-registered-in-russia-oreanda-news 2024-12-27T07:29:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-domestic-drug-for-one-type-of-cancer-has-been-registered-in-russia-oreanda-news 2024-12-27T07:29:11+00:00 weekly 0.7 https://trial.medpath.com/news/radiation-oncology-pioneer-ralph-weichselbaum-named-2024-giants-of-cancer-care-inductee 2024-12-27T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radiation-oncology-pioneer-ralph-weichselbaum-named-2024-giants-of-cancer-care-inductee 2024-12-27T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ausperbio-secures-73-million-in-series-b-financing-to-advance-functional-cure-for-biospace 2024-12-27T05:00:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ausperbio-secures-73-million-in-series-b-financing-to-advance-functional-cure-for-biospace 2024-12-27T05:00:46+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-developments-in-waldenstrom-macroglobulinemia-treatment-btk-inhibitors-and-novel-therapies-show-promise 2024-12-27T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-developments-in-waldenstrom-macroglobulinemia-treatment-btk-inhibitors-and-novel-therapies-show-promise 2024-12-27T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/exicure-inc-partners-with-gpcr-therapeutics-to-fuel-new-growth-in-biotech-stock-titan 2024-12-27T03:18:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exicure-inc-partners-with-gpcr-therapeutics-to-fuel-new-growth-in-biotech-stock-titan 2024-12-27T03:18:57+00:00 weekly 0.7 https://trial.medpath.com/news/sbrt-plus-sorafenib-boosts-os-over-sorafenib-alone-for-hcc-docwire-news 2024-12-27T01:14:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sbrt-plus-sorafenib-boosts-os-over-sorafenib-alone-for-hcc-docwire-news 2024-12-27T01:14:22+00:00 weekly 0.7 https://trial.medpath.com/news/enterprise-generative-ai-in-pharma-navigating-cautious-adoption-for-transformative-impact 2024-12-27T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enterprise-generative-ai-in-pharma-navigating-cautious-adoption-for-transformative-impact 2024-12-27T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-study-identifies-five-distinct-alzheimer-s-subtypes-paving-way-for-personalized-treatment 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-study-identifies-five-distinct-alzheimer-s-subtypes-paving-way-for-personalized-treatment 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adhd-medication-shows-promise-in-treating-methamphetamine-dependence 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adhd-medication-shows-promise-in-treating-methamphetamine-dependence 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/innate-pharma-unveils-growth-strategy-and-highlights-clinical-trial-progress 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innate-pharma-unveils-growth-strategy-and-highlights-clinical-trial-progress 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rpt193-drug-hunter 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rpt193-drug-hunter 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tumor-mutational-burden-may-guide-treatment-in-metastatic-breast-cancer 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tumor-mutational-burden-may-guide-treatment-in-metastatic-breast-cancer 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/immupharma-lon-imm-trading-down-7-3-here-s-why 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immupharma-lon-imm-trading-down-7-3-here-s-why 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-advances-in-ophthalmology-2024-highlights 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-advances-in-ophthalmology-2024-highlights 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/recent-advances-in-medical-treatments-and-regulatory-approvals 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recent-advances-in-medical-treatments-and-regulatory-approvals 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/madrigal-pharmaceuticals-advances-in-nash-treatment-with-resmetirom-phase-3-trials 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/madrigal-pharmaceuticals-advances-in-nash-treatment-with-resmetirom-phase-3-trials 2024-12-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/viracta-therapeutics-announces-closure-of-naval-1-clinical-globenewswire 2024-12-26T21:34:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viracta-therapeutics-announces-closure-of-naval-1-clinical-globenewswire 2024-12-26T21:34:14+00:00 weekly 0.7 https://trial.medpath.com/news/psychedelic-alpha-s-top-11-stories-from-2024 2024-12-26T21:30:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psychedelic-alpha-s-top-11-stories-from-2024 2024-12-26T21:30:44+00:00 weekly 0.7 https://trial.medpath.com/news/cardiology-year-in-review-2024-hcplive 2024-12-26T21:04:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiology-year-in-review-2024-hcplive 2024-12-26T21:04:23+00:00 weekly 0.7 https://trial.medpath.com/news/tislelizumab-triplet-shows-meaningful-responses-pfs-in-metastatic-tnbc 2024-12-26T21:02:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tislelizumab-triplet-shows-meaningful-responses-pfs-in-metastatic-tnbc 2024-12-26T21:02:46+00:00 weekly 0.7 https://trial.medpath.com/news/sermonix-and-henlius-dose-first-chinese-patient-in-phase-3-globenewswire 2024-12-26T20:42:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sermonix-and-henlius-dose-first-chinese-patient-in-phase-3-globenewswire 2024-12-26T20:42:06+00:00 weekly 0.7 https://trial.medpath.com/news/ohtuvayre-from-verona-pharma-pharmacy-times 2024-12-26T20:06:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ohtuvayre-from-verona-pharma-pharmacy-times 2024-12-26T20:06:41+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-may-increase-aes-in-hr-her2-breast-cancer-treatment 2024-12-26T19:08:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tirzepatide-may-increase-aes-in-hr-her2-breast-cancer-treatment 2024-12-26T19:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/cardiology-most-read-stories-from-2024-drug-topics 2024-12-26T17:51:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiology-most-read-stories-from-2024-drug-topics 2024-12-26T17:51:20+00:00 weekly 0.7 https://trial.medpath.com/news/preliminary-evidence-of-renal-function-improvement-newswise 2024-12-26T17:23:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/preliminary-evidence-of-renal-function-improvement-newswise 2024-12-26T17:23:08+00:00 weekly 0.7 https://trial.medpath.com/news/the-affects-of-env-101-on-ipf-pharmaceutical-executive 2024-12-26T17:15:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-affects-of-env-101-on-ipf-pharmaceutical-executive 2024-12-26T17:15:47+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-pharmaceuticals-stock-is-down-13-here-s-why-you-should-buy-the-dip 2024-12-26T16:55:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vertex-pharmaceuticals-stock-is-down-13-here-s-why-you-should-buy-the-dip 2024-12-26T16:55:11+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-stock-roundup-nvo-s-obesity-study-failure-fda-nod-to-pfe-lly-barchart-com 2024-12-26T16:25:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-stock-roundup-nvo-s-obesity-study-failure-fda-nod-to-pfe-lly-barchart-com 2024-12-26T16:25:34+00:00 weekly 0.7 https://trial.medpath.com/news/top-5-stories-from-the-2024-san-antonio-breast-cancer-symposium-cure-today 2024-12-26T16:06:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-5-stories-from-the-2024-san-antonio-breast-cancer-symposium-cure-today 2024-12-26T16:06:48+00:00 weekly 0.7 https://trial.medpath.com/news/immunogenicity-reactogenicity-and-safety-of-a-pentavalent-meningococcal-abcwy-pubmed 2024-12-26T15:58:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunogenicity-reactogenicity-and-safety-of-a-pentavalent-meningococcal-abcwy-pubmed 2024-12-26T15:58:26+00:00 weekly 0.7 https://trial.medpath.com/news/os-therapies-partners-with-b2i-digital-to-engage-with-biotech-investors-online-stock-titan 2024-12-26T15:23:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/os-therapies-partners-with-b2i-digital-to-engage-with-biotech-investors-online-stock-titan 2024-12-26T15:23:47+00:00 weekly 0.7 https://trial.medpath.com/news/rx-road-map-erdafitinib-balversa-oncology-nursing-news 2024-12-26T15:02:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rx-road-map-erdafitinib-balversa-oncology-nursing-news 2024-12-26T15:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/effect-of-individualized-versus-conventional-perioperative-blood-pressure-management-on-trials 2024-12-26T14:33:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effect-of-individualized-versus-conventional-perioperative-blood-pressure-management-on-trials 2024-12-26T14:33:52+00:00 weekly 0.7 https://trial.medpath.com/news/casi-pharmaceuticals-faces-clinical-hold-on-cid-103-by-fda-tipranks-com 2024-12-26T14:00:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/casi-pharmaceuticals-faces-clinical-hold-on-cid-103-by-fda-tipranks-com 2024-12-26T14:00:09+00:00 weekly 0.7 https://trial.medpath.com/news/assembly-biosciences-reports-interim-phase-1b-results-from-clinical-trial-evaluating-next 2024-12-26T13:16:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/assembly-biosciences-reports-interim-phase-1b-results-from-clinical-trial-evaluating-next 2024-12-26T13:16:32+00:00 weekly 0.7 https://trial.medpath.com/news/the-chase-for-novel-oral-glp-1-obesity-meds-adds-a-new-contender-medcity-news 2024-12-26T13:11:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-chase-for-novel-oral-glp-1-obesity-meds-adds-a-new-contender-medcity-news 2024-12-26T13:11:37+00:00 weekly 0.7 https://trial.medpath.com/news/managing-young-mpn-patients-balancing-long-term-treatment-risks-and-benefits 2024-12-26T12:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/managing-young-mpn-patients-balancing-long-term-treatment-risks-and-benefits 2024-12-26T12:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/palvella-therapeutics-stock-gains-attention-with-phase-3-trial-data-expected-in-early-2026 2024-12-26T12:23:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/palvella-therapeutics-stock-gains-attention-with-phase-3-trial-data-expected-in-early-2026 2024-12-26T12:23:31+00:00 weekly 0.7 https://trial.medpath.com/news/polypid-stock-poised-for-2026-launch-despite-adjusted-target-from-hc-wainwright 2024-12-26T12:23:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/polypid-stock-poised-for-2026-launch-despite-adjusted-target-from-hc-wainwright 2024-12-26T12:23:30+00:00 weekly 0.7 https://trial.medpath.com/news/genomic-scarring-score-predicts-the-response-to-parp-inhibitors-in-non-small-cell-lung-cancer 2024-12-26T12:22:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genomic-scarring-score-predicts-the-response-to-parp-inhibitors-in-non-small-cell-lung-cancer 2024-12-26T12:22:14+00:00 weekly 0.7 https://trial.medpath.com/news/neurologylive-r-year-in-review-2024-top-conference-coverage-stories 2024-12-26T11:33:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurologylive-r-year-in-review-2024-top-conference-coverage-stories 2024-12-26T11:33:13+00:00 weekly 0.7 https://trial.medpath.com/news/microtech-announces-first-human-case-of-implantable-microsensor-for-heart-failure 2024-12-26T11:20:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/microtech-announces-first-human-case-of-implantable-microsensor-for-heart-failure 2024-12-26T11:20:11+00:00 weekly 0.7 https://trial.medpath.com/news/ind-application-for-a-phase-i-ii-clinical-study-of-anti-her2-bispecific-adc-subcutaneous 2024-12-26T09:49:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ind-application-for-a-phase-i-ii-clinical-study-of-anti-her2-bispecific-adc-subcutaneous 2024-12-26T09:49:33+00:00 weekly 0.7 https://trial.medpath.com/news/dravet-syndrome-severe-myoclonic-epilepsy-of-infancy-global-clinical-trials-review-2024 2024-12-26T09:37:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dravet-syndrome-severe-myoclonic-epilepsy-of-infancy-global-clinical-trials-review-2024 2024-12-26T09:37:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-mandates-standardized-asbestos-testing-protocol-for-talc-based-cosmetics 2024-12-26T09:33:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-mandates-standardized-asbestos-testing-protocol-for-talc-based-cosmetics 2024-12-26T09:33:31+00:00 weekly 0.7 https://trial.medpath.com/news/tiumbio-s-hemophilia-novel-drug-candidate-tu7710-achieves-successful-results-in-phase 2024-12-26T07:11:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tiumbio-s-hemophilia-novel-drug-candidate-tu7710-achieves-successful-results-in-phase 2024-12-26T07:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/novel-research-reveals-uchl1-as-therapeutic-target-in-ovarian-cancer-and-western-diet-s-impact-on-liver-cancer 2024-12-26T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-research-reveals-uchl1-as-therapeutic-target-in-ovarian-cancer-and-western-diet-s-impact-on-liver-cancer 2024-12-26T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-data-validates-venetoclax-s-efficacy-in-cll-patients-after-btk-inhibitor-treatment 2024-12-26T06:17:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-data-validates-venetoclax-s-efficacy-in-cll-patients-after-btk-inhibitor-treatment 2024-12-26T06:17:00+00:00 weekly 0.7 https://trial.medpath.com/news/georgetown-oncologist-dr-john-marshall-s-journey-from-personal-loss-to-pioneering-gi-cancer-care 2024-12-26T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/georgetown-oncologist-dr-john-marshall-s-journey-from-personal-loss-to-pioneering-gi-cancer-care 2024-12-26T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/key-copd-research-highlights-mortality-risks-treatment-effects-and-biomarkers-in-2024 2024-12-26T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/key-copd-research-highlights-mortality-risks-treatment-effects-and-biomarkers-in-2024 2024-12-26T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharmacy-prescribing-trials-provide-access-to-immediate-care-hmri 2024-12-26T05:28:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmacy-prescribing-trials-provide-access-to-immediate-care-hmri 2024-12-26T05:28:25+00:00 weekly 0.7 https://trial.medpath.com/news/lirodegimod-drug-targets-indications-patents 2024-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lirodegimod-drug-targets-indications-patents 2024-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rxrx-stock-surges-with-promising-trials-whats-next-for-investors 2024-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rxrx-stock-surges-with-promising-trials-whats-next-for-investors 2024-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/systemic-sclerosis-clinical-trials-2024-ema-pdma-fda 2024-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/systemic-sclerosis-clinical-trials-2024-ema-pdma-fda 2024-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/telisotuzumab-vedotin-shows-promise-in-treating-c-met-positive-non-small-cell-lung-cancer 2024-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/telisotuzumab-vedotin-shows-promise-in-treating-c-met-positive-non-small-cell-lung-cancer 2024-12-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-emotional-therapy-shows-superior-pain-reduction-in-veterans-compared-to-cbt 2024-12-25T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-emotional-therapy-shows-superior-pain-reduction-in-veterans-compared-to-cbt 2024-12-25T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/automated-insulin-delivery-systems-enhance-glycaemic-control-in-youth-with-type-1-diabetes 2024-12-25T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/automated-insulin-delivery-systems-enhance-glycaemic-control-in-youth-with-type-1-diabetes 2024-12-25T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-keytruda-faces-new-competition-in-cancer-treatment-arena 2024-12-25T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-s-keytruda-faces-new-competition-in-cancer-treatment-arena 2024-12-25T23:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/xanomeline-trospium-chloride-first-approval-springermedicine-com 2024-12-25T23:45:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xanomeline-trospium-chloride-first-approval-springermedicine-com 2024-12-25T23:45:02+00:00 weekly 0.7 https://trial.medpath.com/news/gecacitinib-demonstrates-safety-efficacy-over-hydroxyurea-in-patients-with-myelofibrosis 2024-12-25T23:06:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gecacitinib-demonstrates-safety-efficacy-over-hydroxyurea-in-patients-with-myelofibrosis 2024-12-25T23:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/top-5-cancer-vaccine-stories-from-2024-cure-today 2024-12-25T19:14:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-5-cancer-vaccine-stories-from-2024-cure-today 2024-12-25T19:14:13+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-for-alzheimer-s-what-drives-brain-age-primary-care-alzheimer-s-guideline 2024-12-25T18:02:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-for-alzheimer-s-what-drives-brain-age-primary-care-alzheimer-s-guideline 2024-12-25T18:02:11+00:00 weekly 0.7 https://trial.medpath.com/news/biosimilar-market-achieves-major-breakthrough-in-2024-with-61-fda-approvals-and-12-4b-in-healthcare-savings 2024-12-25T17:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biosimilar-market-achieves-major-breakthrough-in-2024-with-61-fda-approvals-and-12-4b-in-healthcare-savings 2024-12-25T17:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/preliminary-results-of-qilu-pharmaceutical-s-phase-ia-study-on-gprc5d-cd3-targeting 2024-12-25T16:57:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/preliminary-results-of-qilu-pharmaceutical-s-phase-ia-study-on-gprc5d-cd3-targeting 2024-12-25T16:57:22+00:00 weekly 0.7 https://trial.medpath.com/news/transcranial-magnetic-stimulation-for-teenage-depression-psychology-today 2024-12-25T15:49:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/transcranial-magnetic-stimulation-for-teenage-depression-psychology-today 2024-12-25T15:49:59+00:00 weekly 0.7 https://trial.medpath.com/news/ropeginterferon-alfa-2b-response-improves-with-nfkb1-haplotype-in-pv-and-et 2024-12-25T15:10:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ropeginterferon-alfa-2b-response-improves-with-nfkb1-haplotype-in-pv-and-et 2024-12-25T15:10:08+00:00 weekly 0.7 https://trial.medpath.com/news/optimizing-infusion-chair-time-for-oncology-trials-follow-up-study 2024-12-25T14:06:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/optimizing-infusion-chair-time-for-oncology-trials-follow-up-study 2024-12-25T14:06:20+00:00 weekly 0.7 https://trial.medpath.com/news/stem-cell-therapy-offers-new-hope-for-children-with-heart-failure 2024-12-25T13:54:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stem-cell-therapy-offers-new-hope-for-children-with-heart-failure 2024-12-25T13:54:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-therapies-and-combinations-augment-melanoma-treatment-arsenal-onclive 2024-12-25T13:07:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-therapies-and-combinations-augment-melanoma-treatment-arsenal-onclive 2024-12-25T13:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/precision-trial-hcplive 2024-12-25T13:03:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precision-trial-hcplive 2024-12-25T13:03:31+00:00 weekly 0.7 https://trial.medpath.com/news/transformative-or-transitional-deciphering-the-role-of-niagara-in-shaping-future-practice 2024-12-25T12:59:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/transformative-or-transitional-deciphering-the-role-of-niagara-in-shaping-future-practice 2024-12-25T12:59:35+00:00 weekly 0.7 https://trial.medpath.com/news/medmira-receives-health-canada-approval-for-its-multiplo-r-rapid-tp-hiv-test-for 2024-12-25T12:38:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medmira-receives-health-canada-approval-for-its-multiplo-r-rapid-tp-hiv-test-for 2024-12-25T12:38:42+00:00 weekly 0.7 https://trial.medpath.com/news/imcivree-label-expanded-weight-loss-with-weekly-injection-kidney-donation-chain 2024-12-25T11:32:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imcivree-label-expanded-weight-loss-with-weekly-injection-kidney-donation-chain 2024-12-25T11:32:20+00:00 weekly 0.7 https://trial.medpath.com/news/dreamm-11-part-2-japanese-phase-i-trial-of-belantamab-mafodotin-combination-therapies 2024-12-25T09:50:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dreamm-11-part-2-japanese-phase-i-trial-of-belantamab-mafodotin-combination-therapies 2024-12-25T09:50:18+00:00 weekly 0.7 https://trial.medpath.com/news/mass-balance-recovery-absorption-metabolism-and-excretion-of-elinzanetant-in-healthy 2024-12-25T09:50:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mass-balance-recovery-absorption-metabolism-and-excretion-of-elinzanetant-in-healthy 2024-12-25T09:50:01+00:00 weekly 0.7 https://trial.medpath.com/news/samsung-bioepis-advances-denosumab-biosimilar-sb16-for-osteoporosis-and-oncology-indications 2024-12-25T09:11:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/samsung-bioepis-advances-denosumab-biosimilar-sb16-for-osteoporosis-and-oncology-indications 2024-12-25T09:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/mindmed-stock-skyrockets-94-year-to-date-what-s-driving-it-yahoo-finance 2024-12-25T08:47:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mindmed-stock-skyrockets-94-year-to-date-what-s-driving-it-yahoo-finance 2024-12-25T08:47:35+00:00 weekly 0.7 https://trial.medpath.com/news/ultragenyx-shares-retain-buy-rating-as-pivotal-phase-3-aspire-study-begins-for-angelman-syndrome 2024-12-25T06:31:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultragenyx-shares-retain-buy-rating-as-pivotal-phase-3-aspire-study-begins-for-angelman-syndrome 2024-12-25T06:31:12+00:00 weekly 0.7 https://trial.medpath.com/news/novel-integrated-palliative-care-training-program-shows-promise-for-hematology-oncology-fellows 2024-12-25T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-integrated-palliative-care-training-program-shows-promise-for-hematology-oncology-fellows 2024-12-25T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/statin-therapy-shows-significant-cardiovascular-risk-reduction-in-elderly-patients-over-75 2024-12-25T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/statin-therapy-shows-significant-cardiovascular-risk-reduction-in-elderly-patients-over-75 2024-12-25T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/brain-foundation-issues-rfp-research-to-benefit-individuals-with-autism-rfps-pnd 2024-12-25T05:21:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brain-foundation-issues-rfp-research-to-benefit-individuals-with-autism-rfps-pnd 2024-12-25T05:21:24+00:00 weekly 0.7 https://trial.medpath.com/news/top-healthcare-experts-share-insights-on-obesity-management-primary-care-innovation-and-health-equity-in-2024-ivbm-coverage 2024-12-25T03:27:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-healthcare-experts-share-insights-on-obesity-management-primary-care-innovation-and-health-equity-in-2024-ivbm-coverage 2024-12-25T03:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/castle-biosciences-reports-preliminary-data-from-atopic-dermatitis-test-study 2024-12-25T02:34:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/castle-biosciences-reports-preliminary-data-from-atopic-dermatitis-test-study 2024-12-25T02:34:41+00:00 weekly 0.7 https://trial.medpath.com/news/basilea-receives-additional-funding-from-carb-x-to-advance-antibiotic-candidate 2024-12-25T00:35:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/basilea-receives-additional-funding-from-carb-x-to-advance-antibiotic-candidate 2024-12-25T00:35:24+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-ingelheim-partners-with-walgreens-for-obesity-and-diabetes-clinical-trial 2024-12-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-ingelheim-partners-with-walgreens-for-obesity-and-diabetes-clinical-trial 2024-12-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ustekinumab-biosimilar-by-celltrion-for-psoriatic-arthritis-likelihood 2024-12-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ustekinumab-biosimilar-by-celltrion-for-psoriatic-arthritis-likelihood 2024-12-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cd20-bispecific-antibodies-show-promise-in-lymphoma-treatment-at-ash 2024-12-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cd20-bispecific-antibodies-show-promise-in-lymphoma-treatment-at-ash 2024-12-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-says-decongestant-in-many-cold-medicines-doesn-t-work-so-what-does-fox-13-memphis 2024-12-24T22:57:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-says-decongestant-in-many-cold-medicines-doesn-t-work-so-what-does-fox-13-memphis 2024-12-24T22:57:28+00:00 weekly 0.7 https://trial.medpath.com/news/guess-which-asx-healthcare-stock-is-jumping-7-on-us-fda-approval-news-motley-fool 2024-12-24T22:38:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/guess-which-asx-healthcare-stock-is-jumping-7-on-us-fda-approval-news-motley-fool 2024-12-24T22:38:35+00:00 weekly 0.7 https://trial.medpath.com/news/new-smartphone-app-successfully-treats-tinnitus-in-clinical-trial-the-brighter-side-of-news 2024-12-24T21:15:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-smartphone-app-successfully-treats-tinnitus-in-clinical-trial-the-brighter-side-of-news 2024-12-24T21:15:12+00:00 weekly 0.7 https://trial.medpath.com/news/autologous-tumor-lysate-loaded-dendritic-cell-vaccination-in-glioblastoma-patients 2024-12-24T21:09:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autologous-tumor-lysate-loaded-dendritic-cell-vaccination-in-glioblastoma-patients 2024-12-24T21:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/new-ptsd-treatment-shows-promise-with-brexpiprazole-sertraline-combination 2024-12-24T19:55:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-ptsd-treatment-shows-promise-with-brexpiprazole-sertraline-combination 2024-12-24T19:55:01+00:00 weekly 0.7 https://trial.medpath.com/news/mariposa-trial-shows-pfs-benefit-with-or-without-cns-disease-in-nsclc 2024-12-24T19:31:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mariposa-trial-shows-pfs-benefit-with-or-without-cns-disease-in-nsclc 2024-12-24T19:31:14+00:00 weekly 0.7 https://trial.medpath.com/news/prophylactic-approaches-lessen-immune-related-reactions-in-nsclc-cancer-network 2024-12-24T19:02:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prophylactic-approaches-lessen-immune-related-reactions-in-nsclc-cancer-network 2024-12-24T19:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-flurry-of-drugs-ahead-of-holiday-season-pharmaphorum 2024-12-24T18:50:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-flurry-of-drugs-ahead-of-holiday-season-pharmaphorum 2024-12-24T18:50:55+00:00 weekly 0.7 https://trial.medpath.com/news/research-supports-need-for-diversity-in-hemophilia-trials-and-reducing-resource-strain 2024-12-24T18:42:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-supports-need-for-diversity-in-hemophilia-trials-and-reducing-resource-strain 2024-12-24T18:42:19+00:00 weekly 0.7 https://trial.medpath.com/news/journey-medical-corporation-announces-fda-approval-of-emrositm-for-rosacea-treatment 2024-12-24T18:25:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/journey-medical-corporation-announces-fda-approval-of-emrositm-for-rosacea-treatment 2024-12-24T18:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/where-do-psychedelics-fit-in-the-future-of-psychiatry-psychiatric-times 2024-12-24T18:06:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/where-do-psychedelics-fit-in-the-future-of-psychiatry-psychiatric-times 2024-12-24T18:06:03+00:00 weekly 0.7 https://trial.medpath.com/news/clearmind-medicine-receives-irb-approval-for-its-fda-regulated-clinical-trial-stock-titan 2024-12-24T17:58:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clearmind-medicine-receives-irb-approval-for-its-fda-regulated-clinical-trial-stock-titan 2024-12-24T17:58:57+00:00 weekly 0.7 https://trial.medpath.com/news/innovation-collaboration-and-performance-were-highlights-for-ema-in-2024-pharmtech 2024-12-24T17:39:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovation-collaboration-and-performance-were-highlights-for-ema-in-2024-pharmtech 2024-12-24T17:39:51+00:00 weekly 0.7 https://trial.medpath.com/news/progress-of-immune-checkpoint-inhibitors-therapy-for-pmmr-mss-metastat-ott 2024-12-24T17:34:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/progress-of-immune-checkpoint-inhibitors-therapy-for-pmmr-mss-metastat-ott 2024-12-24T17:34:41+00:00 weekly 0.7 https://trial.medpath.com/news/biocon-zentiva-get-eu-approval-for-generic-diabetes-weight-management-drug-the-hindu 2024-12-24T17:27:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biocon-zentiva-get-eu-approval-for-generic-diabetes-weight-management-drug-the-hindu 2024-12-24T17:27:14+00:00 weekly 0.7 https://trial.medpath.com/news/hospitals-trial-ai-to-spot-type-2-diabetes-risk-bbc 2024-12-24T15:17:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hospitals-trial-ai-to-spot-type-2-diabetes-risk-bbc 2024-12-24T15:17:11+00:00 weekly 0.7 https://trial.medpath.com/news/ractigen-therapeutics-announces-first-patient-dosed-in-phase-i-clinical-trial-for-rag-17-in 2024-12-24T15:07:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ractigen-therapeutics-announces-first-patient-dosed-in-phase-i-clinical-trial-for-rag-17-in 2024-12-24T15:07:50+00:00 weekly 0.7 https://trial.medpath.com/news/os-therapies-announces-pricing-of-6-million-private-placement-stock-titan 2024-12-24T14:45:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/os-therapies-announces-pricing-of-6-million-private-placement-stock-titan 2024-12-24T14:45:35+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-launched-phase-3-trial-for-ibuzatrelvir-new-oral-antiviral-for-covid-19-treatment 2024-12-24T14:11:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-launched-phase-3-trial-for-ibuzatrelvir-new-oral-antiviral-for-covid-19-treatment 2024-12-24T14:11:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-developments-in-car-t-treatments-webinar-series-summary-cancer-network 2024-12-24T14:02:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-developments-in-car-t-treatments-webinar-series-summary-cancer-network 2024-12-24T14:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/enanta-pharmaceuticals-stock-remains-buy-rated-with-phase-2-data-driving-model-revisions 2024-12-24T14:01:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enanta-pharmaceuticals-stock-remains-buy-rated-with-phase-2-data-driving-model-revisions 2024-12-24T14:01:56+00:00 weekly 0.7 https://trial.medpath.com/news/novel-radiogenomics-approach-to-predict-and-characterize-pneumonitis-in-stage-iii-nsclc 2024-12-24T13:51:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-radiogenomics-approach-to-predict-and-characterize-pneumonitis-in-stage-iii-nsclc 2024-12-24T13:51:48+00:00 weekly 0.7